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Race-ing Patents/Patenting Race: An Emerging Political Geography of
Intellectual Property in Biotechnology
Abstract
This article applies insights from critical race theory to examine an emerging phenomenon in biotechnology
research and product development. The strategic use of race as a genetic category to obtain patent protection
and drug approval. A dramatic rise in the use of race in biotechnology patents indicates that researchers and
affiliated commercial enterprises are coming to see social categories of race as presenting opportunities for
gaining, extending, or protecting monopoly market protection for an array of biotechnological products and
services. Racialized patents are also providing the basis for similarly race-based clinical trial designs, drug
development, capital raising and marketing strategies that carry the implication of constructing of race as
genetic out to ever widening and consequential segments of society.
The introduction of race in the field of patent law as an adjunct to biotechnological inventions producing a
new political geography of intellectual property in which the very metes and bounds of the territory covered
by patents are becoming racially marked. As patents are racialized, racial identity itself is becoming a
patentable commodity whose value is being appropriated to expand market control and extend the market life
of their products. Generally speaking, however, the people capitalizing on race are not necessarily those who
belong to the racially identified groups, but rather those corporations that are literally investing their patents
and products with race to gain commercial advantage in the research, development, and marketing of new
biotechnology products. Patenting race may thus have profound implications both for the equitable
distribution of benefits derived from biotechnology and for broader social understandings and mobilizations
of race.
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I. INTRODUCTION
A new phenomenon is emerging in biotechnology research and
product development-the strategic use of race as a genetic category to
obtain patent protection and drug approval. A dramatic rise in the use of
race in biotechnology and related patents since the completion of the first
draft of the human genome in 2000 indicates that researchers and affiliated
commercial enterprises are coming to see social categories of race as
presenting opportunities for gaining, extending, or protecting monopoly
market protection for an array of biotechnological products and services.'
Racialized patents are also providing the basis for similarly race-based
clinical trial designs, drug development, capital raising, and marketing
strategies that extend the implications of constructing race as genetic to ever
widening and consequential segments of society.
2
The introduction of race to the field of patent law as an adjunct to
biotechnological inventions is producing a new political geography of
intellectual property in which the very "metes and bounds" of the territory
covered by patents are becoming racially marked: As patents are racialized,
racial identity itself is becoming a patentable commodity, the value of which
is being appropriated to expand market control and extend the market life
of products.4 Generally speaking, however, those capitalizing on race are not
necessarily those who belong to the racially identified groups, but rather
corporations that are literally "investing" their patents and products with
race to gain commercial advantage in the research, development, and
marketing of new biotechnology products.5 Patenting race may thus have
profound implications for both the equitable distribution of benefits derived
from biotechnology and for broader social understandings and
mobilizations of race. In this context, law and commerce are driving the use
of race in science and medicine.
Of particular concern is the fact that unlike other attempts at so-called
"ethnic" or "multicultural" niche marketing,6 which simply aim to sell a
variety of products to socially identified racial groups, racialized
biotechnology products and processes are largely premised on
1. See infra text accompanying notes 213-26.
2. See infta text accompanying notes 152-89.
3. "Metes and bounds" is a legal description of a parcel of land that begins at a well-
marked point and follows the boundaries, using directions and distances around the tract, back
to the place of beginning. ROGER E. SCHECHTER &JOHN R. THOMAS, INTELLECTUAL PROPERTY:
THE LAw OF COPYRIGHTS, PATENTS AND TRADEMARKS 404 (2003).
4. See infra text accompanying notes 348-403.
5. See infra text accompanying notes 152-89, 395-403.
6. See, e.g., American Multicultural Marketing, http://americanmulticultural.com/
index.html (last visited Jan. 30, 2006); MarketResearch.com, Multicultural Market Research
Reports, http://www.marketresearch.com/browse.asp?categoryid=135 (last visited Jan. 30,
2006).
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unsubstantiated understandings of race as genetic. 7 When the federal
government grants a patent to an invention that is based on an asserted or
implied genetic basis for a particular racial group, it gives the imprimatur of
the federal government to the construction of race as genetic. Such an
imprimatur opens the door to new forms of discrimination based on
genetically reductive conceptions of racial difference." It may also divert
public resources from socioeconomic health disparities toward more market-
driven commercial strategies for targeting race-based health difference at
the molecular level.9
Most efforts to address potentially discriminatory uses of genetics tend
to focus on the production, circulation, and potential misuse of a particular
individual's genetic information.' 0 Statutes covering these problems tend to
cover issues of privacy, information control, and the evaluation of
individualized medical conditions." Using patent law to identify genetic
conditions with racial groups presents challenges of a different order.
Instead of implicating new forms of discrimination based on specific
individualized genetics, the rebiologization of race in patent law provides
state and commercial sanction to the identification of existing groups that
historically have been subject to various forms of discriminatory treatment,
such as African-Americans, with new genetic categories that are being
produced through advances in genetics. Such identification of social groups
with genetics opens the door to revitalizing racial discrimination in new and
previously unanticipated ways."
Intellectual property law is fully engaged in the pervasive management
of genetic material and information. 14 The rush to patent genetic material
7. See infra text accompanying notes 32-47, 159-89, 292-309, 370-74.
8. See, e.g., Jonathan Kahn, How a Drug Becomes "Ethnic" Law, Commerce, and the Production
of Racial Categories in Medicine, 4 YALE J. HEALTH POL'Y L. & ETHICS 1, 33 (2004) [hereinafter
Kahn, Racial Categories]. See generally Lundy Braun, Race, Ethnicity, and Health: Can Genetics
Explain Disparities?, 45 PERSPECTIVES BIOLOGY MED. 159-74 (2002) (discussing the pitfalls of
using genetic explanations for health disparities).
9. Jonathan Kahn, From Disparity to Difference: How Race-Specific Medicines May Undermine
Policies to Address Inequalities in Health Care, 15 S. CAL. INTERDIsC. L.J. 105, 105-06 (2005)
[hereinafter Kahn, Disparity].
10. See generally RUTH HUBBARD & ELIJAH WALD, EXPLODING THE GENE MYrH (1999)
(discussing production and manipulation of genetic information); GENETIC SECRETS (Mark A.
Rothstein ed., 1997); GENETICS AND LIFE INSURANCE (Mark A. Rothstein ed., 2004).
11. See, e.g., Nancy Kass, The Implications of Genetic Testing for Health and Life Insurance, in
GENETIC SECRETS, supra note 10, at 299, 299-316; Mark A. Rothstein, The Law of Medical and
Genetic Privacy in the Workplace, in GENETIC SECRETS, supra note 10, at 281,281-98.
12. See generally Susan M. Wolf, Beyond "Genetic Discrimination": Toward the Broader Harm of
Geneticism, 23J.L. MED. & ETHICS 345 (1995).
13. See, e.g., Patricia A. King, The Dangers of Difference, HASTINGS CENTER REP., Nov.-Dec.
1992, at 35; Sandra Soo-Jin Lee et al., The Meanings of "Race" in the New Genomics: Implications for
Health Disparities Research, I YALEJ. HEALTH POL'Y L. & ETHICS 33 passim (2001).
14. See, e.g., MICHALEJ. MALINOWSKI & BETH E. ARNOLD, BIOTECHNOLOGY: LAW, BUSINESS,
REGULATION §§ 2.01-07 (Supp. 2002).
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has implicated existing patent law to a much greater degree than most other
areas of law. While many ethical, legal, and commercial implications of
patenting human genetic material have been explored at length," little
attention has been given to the ways in which social categories of race and
ethnicity are increasingly being mobilized in the context of biotechnology
patents.
As biotechnology patents become racialized, they are driving broader
scientific, political, and public understandings and uses of racial categories.
The scope of patent protection is typically referred to in terms of "metes and
bounds."1 6 The metaphors of physical property are quite deliberate. New
biotechnology patents are systematically racializing the "metes and bounds"
of the intellectual property claims.' 7 As scholars such as Cheryl Harris and
Richard Thompson Ford have noted, American law has a long tradition of
characterizing property and physical spaces in racial terms--often to
devastating effect. 8 Whether in the most egregious and obvious form of
race-based slavery or in subtler identifications of neighborhoods or even
names making it more difficult to obtain mortgages or jobs because of their
association with a certain race, the nature and value of property has long
been influenced profoundly in and through its association with race. 9
Previous associations of race and property have generally involved a
devaluing of associations with racial minorities while investing Whiteness
with added value. As Tom Romero notes in commenting on the work of
15. See generally E. RICHARD GOLD, BODY PARTS: PROPERTY RIGHTS AND THE OWNERSHIP OF
HUMAN BIOLOGICAL MATERIALS 64-85 (1996) (discussing the reasoning of courts in considering
patents for "revolutionary technologies," including living organisms); Rebecca S. Eisenberg &
Robert P. Merges, Opinion Letter as to the Patentability of Certain Inventions Associated with the
Identiication of Partial cDNA Sequences, 23 AIPLA Q.J. 1 (1995) (analyzing the patentability of
cDNA sequences); Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The
Anticommons in Biomedical Research, 280 SCIENCE 698 (1998);Jonathan Kahn, Biotechnology and the
Legal Constitution of the Self" Managing Identity in Science, the Markets and Society, 51 HASTINGS L.J.
909 (2000) [hereinafter Kahn, Biotechnology and the Legal Constitution of the Se] (discussing
property and tort rights with regard to one's bodily organs) ;Jonathan Kahn, What's the Use? Law
and Authority in Patenting Human Genetic Material, 14 STAN. L. & POL'Y REV. 417 (2003)
[hereinafter Kahn, What's the Use?]; Arti K. Rai, Fostering Cumulative Innovation in the
Biopharmaceutical Industry: The Role of Patents and Antitrust, 16 BERKELEY TECH. L.J. 813 (2001);
Arti Rai, Intellectual Property Rights in Biotechnology: Addressing New Technology, 34 WAKE FOREST L.
REv. 827 (1999); National Academy of Sciences, Intellectual Property Rights and Research Tools
in Molecular Biology, Feb. 15-16, 1996, http://www.nap.edu/readingroom/books/property/
(summarizing a workshop held at the National Academy of Sciences); National Academy of
Sciences, Intellectual Property Rights: How Far Should They Be Extended, Feb. 2-3, 2000,
http://www7.nationalacademies.org/step/STEPProjectsFeb_IPR.Conf._Agenda.html.
16. SCHECTER & THOMAS, supra note 3, at 404.
17. See infra text accompanying notes 348-403.
18. Richard Thompson Ford, The Boundaries of Race: Political Geography in Legal Analysis,
107 HARv. L. REv. 1841, 1847-57 (1994); Cheryl 1. Harris, Whiteness as Property, 106 HARv. L. REv.
1707,1716-24 (1993).
19. Ford, supra note 18, at 1847-57, 1870-78; Harris, supra note 18, at 1713-16.
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George Lipsitz,2° "For much of American history, Americans-from popular
cultural norms to legislation and jurisprudence-have explicitly and
implicitly encouraged a 'possessive investment' in whiteness as the
penultimate marker of access to opportunities and rewards. In contrast,
more recent legal classifications of race, as in affirmative action, have the
potential to challenge exclusionary conceptions of racialized property
rights.2 2 Indeed, since the 1960s, new civil-rights and fair-housing laws
combined with the ebb and flow of affirmative action initiatives have
provided American minorities a substantial, if tenuous, counterpart to a
C~6"23possessive investment' in whiteness.
At first blush, the racialization of biotechnology patents appears to be
more in line with assertedly benign uses of racial categories. Hence the
readiness of such groups as the Association of Black Cardiologists and the
Congressional Black Caucus to support the development of the heart-failure
24drug BiDil, the first drug ever approved by the Food and Drug
Administration ("FDA") with a race-specific indication, to treat heart failure
25only in African Americans. In this regard, BiDil has gained cultural capital
by its characterization as a means to redress an important health disparity in
a historically underserved population. Unlike affirmative action, however,
the underlying patents and commercial-market value of BiDil gave new
meaning to a concept of a "possessive investment" in "Blackness." The
health of Black people (and others) may ultimately benefit from the drug,
but not because of their racial identity.2 6 Rather, it is NitroMed, the
corporate sponsor of BiDil, that "invested" the drug with race, and it is also
NitroMed that is reaping the commercial benefits of thirteen additional
years of patent protection provided from appropriating race to mark its
product.
27
Part II of this Article introduces broad themes and issues concerning
the relationship between race and genetics in biotechnology. It focuses in
particular on the field of personalized medicines, known as
pharmacogenomics, to explore the emerging use of race to capitalize on
20. See generally GEORGE LIPSITZ, THE POSSESSIVE INVESTMENT IN WHITENESS: How WHITE
PEOPLE PROFIT FROM IDENTIIY POLITICS (1998).
21. Tom I. Romero II, War of a Much Different Kind: Poverty and the Possessive Investment in
Color in the Multicultural 1960 United States, 26 UCLA CHIcANo-LATINO L. REV. (forthcoming
2007) (manuscript at 5, on file with the Iowa Law Review).
22. Harris, supra note 18, at 1777-91.
23. Romero, supra note 21 (manuscript at 5) (citing LIPSITZ, supra note 20).
24. Kahn, Racial Categories, supra note 8, at 23.
25. U.S. Food & Drug Admin., FDA Approves BiDil Heart Failure Drug for Black Patients, FDA
NEWS,June 23, 2005, http://www.fda.gov/bbs/topics/NEWS/2005/NEW01190.htrnl.
26. No data exists to support any claim that the drug works differently or better in African
Americans than in anyone else. See generally Jonathan Kahn, "Ethnic" Drugs, HASTINGS CENTER
REP.,Jan.-Feb. 2005, at back cover [hereinafter Kahn, Ethnic].
27. See infra text accompanying notes 152-89.
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new product development. Parts III and IV consider how existing federal
mandates provide structural incentives that teach researchers and clinicians
to "see" race in places they may not otherwise have perceived it. Part III
examines these federal mandates as they structure the collection,
classification, and circulation of data about race and ethnicity. It focuses on
the distinctive influence of the Office of Management and Budget's
Directive 15, "Standard for Maintaining, Collecting, and Presenting Federal
Data on Race and Ethnicity," 8 in structuring and mandating the collection
of such data. Directive 15 explicitly acknowledges that the racial categories it
provides (for example, in collecting census data) are social in character, not
biological or genetic. 29 Nonetheless, it also provides the basis for other
federal directives that mandate the collection of racial and ethnic data in
biomedical contexts where the opportunities for conflating social categories
of race and ethnicity with genetic-population categories become more
pronounced. Part IV examines similar federal initiatives that have played a
profound role in collecting, organizing, and circulating genetic information
produced by scientific and medical researchers from around the world.
When brought together in the context of biotechnology research and
product development, these diverse federal classificatory schemes become
easily entangled and conflated, providing a structural incentive for reifying
race as genetic.:
Part V proceeds to a brief discussion of BiDil, the first drug ever
approved by the FDA with a race-specific indication, for the treatment of
heart failure in African Americans. It argues that the dynamic whereby
commercial and legal considerations drove the development of BiDil is a
portent of further commercial exploitation of race in biotechnology. Part VI
moves on to a detailed analysis of specific new racial patents in
biotechnology, exploring the myriad of ways in which the legal imperatives
of patent law are appropriating the language of science and medicine to
imbue products with new commodity value by reifying race as genetic.
Part VII considers some of the broader theoretical implications of racial
biotechnology patents and explores an emerging political geography of
intellectual property law. This Section brings insights from critical race
theory and critical legal geography to bear on intellectual property. It begins
by considering what race adds to these patents. Race enters the world of
patent law as a social category, considered to be unproblematic, transparent,
28. See generally U.S. Office of Management and Budget: Revisions to the Standards for the
Classification of Federal Data on Race and Ethnicity, 62 Fed. Reg. 58,782, 58,782 (Oct. 30,
1997) [hereinafter OMB, Revisions], available at http://www.whitehouse.gov/
omb/fedreg/ombdirl5.html (revising and evaluating the standards concerning Directive 15).
29. Id.
30. See infra text accompanying notes 99-151.
31. For a brief discussion of the conception of reification of race, see Troy Duster, Race
and Reification in Science, 307 SCIENCE 1050, 1050-51 (2005).
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and easily recognizable. In the process of being integrated into substantive
patent claims, race is transformed from an obvious social category into a
purportedly novel and non-obvious genetic category. In ratifying racialized
patents, the legal regime of intellectual property is indirectly constructing
new, legally sanctioned conceptions of race as a genetic category.
Considering the power of spatial metaphors in intellectual property, this
Section explores how patenting race produces a new segregated genome
with racially marked neighborhoods of DNA being associated with particular
pathologies or utilities. This Article concludes with the observation that
biotechnology corporations are mining the raw material of race as a social
category and using the patent process to refine it into a natural construct in
order to gain patent protection and market advantage. The new commodity
value of patented race depends on its ultimate relation to living, breathing
people who identify with particular racial groups. In the end, though, it is
biotechnology corporations who are appropriating race to their own benefit.
II. RACE, GENES, AND DRUG DEVELOPMENT
To appreciate the significance of the use of race in patents it is helpful
to have an understanding of some basic concepts of genetics. The human
genome is comprised of all the Deoxyribonucleic Acid ("DNA") a person
possesses.32 DNA is composed of ordered combinations of four nucleotide
bases: adenine, guanine, thymine, and cytosine-generally abbreviated as A,
G, T, and C. 3 The human genome contains an estimated three billion
nucleotide bases. 4 A single nucleotide polymorphism or "SNP" is a DNA
sequence variation that occurs when a single nucleotide (A, T, C, or G) in
the genome sequence is altered. 5 Genes are arrays of nucleotides that code
for the production of proteins.36 An allele is an alternative form of any
particular gene.3' Although humans are 99.9% genetically the same, that
.1% variation amounts to about three million variations. 3 With so many
variations, it is often possible to find certain variations occurring in different
frequencies between different groups of individuals. As sociologist Troy
Duster noted:
32. National Human Genome Research Institute (NHGRI), A Brief Guide to Genomics,
http://www.genome.gov/18016863 (last visited Oct. 16, 2006).
33. Id.
34. Id.
35. NHGRI, SNPs, http://www.genome.gov/glossary.cfm (search for "SNPs") (last visited
Oct. 4, 2006).
36. NHGRI, Gene, http://www.genome.gov/glossary.cfm (search for "gene") (last visited
Oct. 4, 2006).
37. NHGRI, Allele, http://www.genome.gov/glossary.cfm (search for "allele") (last visited
Oct. 4, 2006).
38. Francis Collins, What We Do and Don't Know About 'Race,' 'Ethnicity,' Genetics and Health
at the Dawn of the Genome Era, 36 NATURE GENETICS SUPPLEMENT SI 3-15 (2004).
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It is possible to make arbitrary groupings of populations
(geographic, linguistic, self-identified by faith, identified by others
by physiognomy, etc.) and still find statistically significant allelic
variations between those groupings. For example, we could
examine all the people in Chicago, and all those in Los Angeles,
and find statistically significant differences in allele frequency at
some loci. Of course, at many loci, even most loci, we would not find
statistically significant differences.
Given that researchers may find differences in allele frequencies between
Chicagoans and Los Angelinos, it is hardly surprising that they may find
differences between groups somehow marked as "Black," "White," or
"Asian." The difficulty comes when researchers try to assign particular
meanings to such variation.
Since the inception of the Human Genome Project, researchers have
devoted much time and attention to insuring that others do not use
biological knowledge emerging from advances in genetic research
inappropriately to make socially constructed racial40 categories appear
biologically given or "natural."
41 Race is not a coherent genetic concept.
42
Rather, race is best understood as a complex and dynamic social construct.
43
Since the 1970s, scientists have understood that race will statistically explain
only a small portion of human variation. 4 As a 2001 editorial in Nature
39. Troy Duster, Buried Alive: The Concept of Race in Science, in GENETIC NATURE/CULTURE
258, 265 (A. Goodman et al. eds., 2003).
40. In the interests of economy and manageable syntax, in the remainder of this Article, I
will often refer only to "race" when speaking generally of racial and ethnic categories. I am
assuming both to be socially constructed categories that nonetheless have biological
implications as they play out in real world biomedical contexts. I will use the terms "race"
and/or "ethnic" when referring to specifically marked groups. Thus, for example, the U.S.
Census codes "White" or "Asian" as racial categories and "Hispanic" or "Latino" as ethnic
categories.
41. See, e.g., THE HUMAN GENOME PROJECT AND MINORITY COMMUNITIES: ETHICAL, SOCIAL,
AND POLITICAL DILEMMAS passim (Raymond A. Zilinskas & PeterJ. Balint eds., 2000);JONATHAN
MARKS, HUMAN BIODIVERSITY: GENES, RACE AND HISTORY passim (1995); Lisa Gannett, Racism
and Human Genome Diversity Research: The Ethical Limits of 'Population Thinking,' 68 PHIL. OF SCI.
S479, S479-92 (2001) (reporting proceedings of the 2000 Biennial Meetings of the Philosophy
of Science Association); Henry T. Greely, Human Genome Diversity: What About the Other Human
Genome Project?, 2 NATURE REV. GENETICS 222 passim (2001); Debra Harry, The Human Genome
Diversity Project and Its Implications for Indigenous Peoples, 1 GENE WATCH 8, 8-9 (1996); Margaret
Lock, Genetic Diversity and the Politics of Dfference, 75 CHI.-KENT L. REV. 83 passim (1999).
42. Collins, supra note 38, at S13-14.
43. See, e.g., American Anthropological Association (AAA), Response to OMB Directive 15:
Race and Ethnic Standards for Federal Statistics and Administrative Reporting (1997),
http://www.aaanet.org/gvt/ombdraft.htm [hereinafter AAA, Response]; AAA, Statement on
Race (1998), http://www.aaanet.org/stmts/racepp.htm [hereinafter AAA, Statement].
44. Richard C. Lewontin, The Apportionment of Human Diversity, 6 EVOLUTIONARY BIOLOGY
381, 381-84 (1972). For an excellent overview of the history of scientific and cultural
understandings of race, see generally MARKS, supra, note 41.
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Genetics put it, "scientists have long been saying that at the genetic level there
is more variation between two individuals in the same population than
between populations and that there is no biological basis for 'race.' 45 More
recently, an editorial in Nature Biotechnology asserted, "Race is simply a
poor proxy for the environmental and genetic causes of disease or drug
response. . . Pooling people in race silos is akin to zoologists grouping
raccoons, tigers and okapis on the basis that they are all stripey."46 Much
attention has also been devoted to the question of how, whether, or when to
patent human genetic material.4 7 To date, however, there has been little
consideration of the relationship between the two.
The field of drug development is a primary site for the intersection of
race, genetics, and patent law. The new field of pharmacogenomics involves
48attempts to tailor drugs to an individual's genetic profile. It represents one
of the most powerful envisioned applications of the new genetics since the
inception of the Human Genome Project. 49 One commentary defines
pharmacogenomics as "the study of genetic variability in the way people
respond to medicines, traced to the expression of genes related to disease
susceptibility and drug response at the cellular, tissue, individual and
population levels." 50 For every drug, there are some individuals who will
respond better, worse, or not at all, depending in part on their genes.5'
Some genes also play a substantial role in regulating how the body
metabolizes particular drugs.52 Determining whether an individual would
metabolize a drug more quickly or slowly than another due to his or her
genetic profile may help to find the optimal dosage for a particular drug.'3
While the multi-billion dollar Human Genome Project has been slow to
deliver on so-called genetic therapies, it has produced information that
undergirds current attempts by a wide array of biomedical researchers and
pharmaceutical corporations to develop pharmacogenomically tailored
medicines.54
45. Editorial, Genes, Drugs and Race, 29 NATURE GENETICS 239, 239 (2001).
46. Editorial, illuminating BiDi, 23 NATURE BIOTECH. 903, 903 (2005).
47. See, e.g., Kahn, What's the Use, supra note 15, passim.
48. Michelle Meadows, Genomics and Personalized Medicine, FDA CONSUMER MAG., Nov.-
Dec. 2005, available at http://www.fda.gov/fdac/features/2005/605_genomics.html.
49. See generally PHARMACOGENOMICS: SOCIAL, ETHICAL, AND CLINICAL DIMENSIONS (Mark
A. Rothstein ed.,John Wiley & Sons 2003).
50. Barbara J. Evans et al., Creating Incentives for Genomic Research to Improve Targeting of
Therapies, 10 NATURE MED. 1289, 1289 (2004).
51. Meadows, supra note 48.
52. Francis S. Collins, Victor A. McKusick & Karin Jegalian, Implications of the Genome Project
for Medical Science, http://www.genome.gov/Pages/Education/Kit/main.cfm?pageid=188 (last
visited Oct. 9, 2006).
53. Id.
54. Sandra Soo-Jin Lee, Race, Distributive Justice and the Promise of Pharmacogenomics: Ethical
Considerations, 3 AM.J. PHARMACOGENOMICS 385, 385-87 (2003).
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The promise of pharmacogenomics also raises concerns that the
creation of new categories for diagnostic and therapeutic intervention may
reflect or be mapped upon existing social categories of race, class, gender,
and ethnicity in a harmful manner. 5 Some analysts argue that drug-trial data
has shown drug responses that may vary among certain ethnic groups. 6 A
recent article in Nature Genetics brings this issue into bold relief, identifying
twenty-nine drugs that have been claimed, in peer-review, scientific, or
medical journals, to have differences either in safety or, more commonly,
efficacy among racial or ethnic groups: As differential drug response
becomes correlated with race and ethnicity there emerges commercial and
regulatory incentives to recast drug development and gene patenting along
racial lines in order to facilitate regulatory approvals and/or extend market
control.58
This phenomenon has already begun to happen. In June 2005, a drug
called "BiDil" became the first drug ever approved by the FDA with a race-
specific indication: to treat heart failure in African Americans.5 The story of
BiDil is one of how race and ethnicity are used in conjunction with patent
law and the drug-approval process to bring a new drug to market.6°
Underlying the New Drug Application ("NDA") that NitroMed submitted
for this drug to the FDA is a race-specific methods patent: to use the drug
for treatment of heart failure in an African American patient. 61 The patent
is premised on underlying assumptions regarding race and the genetic basis
55. Amalia M. Issa, Ethical Perspectives on Pharmacogenomics Profiling in the Drug Development
Process, 1 NATURE REVIEWS DRUG DISCOVERY 300, 300-01 (2002); Lee, supra note 54, at 385-87;
Mark A. Rothstein & Phyllis G. Epps, Ethical and Legal Implications of Pharmacogenomics, 2 NATURE
REVIEWS GENETICS 228, 228 (2001) [hereinafter Rothstein, Ethical]; MA Rothstein & PG Epps,
Pharmacogenomics and the (Ir)relevance of Race, I PHARMACOGENOMIC J. 104, 105-07 (2001)
[hereinafter Rothstein, Pharmacogenomics].
56. See, e.g., Edward Carlini et al., Sufation Pharmacogenetics: SULTIA1 and SULT1A2 Allele
Frequencies in Caucasian, Chinese and African-American Subjects, 11 PHARMACOGENETICS 57, 57-68
(2001); Peter Kuelh et al., Sequence Diversity in CYP3A Promoters and Characterization of the Genetic
Basis of Polymorphic CYP3A5 Expression, 2 NATURE REVIEWS GENETICS 383, 383 (2001); AlastairJJ.
Wood, Racial Differences in Response to Drugs-Pointers to Genetic Differences, 344 NEW ENG. J. MED.
1393, 1393-95 (2001).
57. See generally Sara K. Tate & David B. Goldstein, Will Tomorrow's Medicines Work for
Everyone?, 36 NATURE GENETICS S34 (2004).
58. Jonathan Kahn, Exploiting Race in Drug Development: BiDil's Interim Model of
Pharmacogenomics, SOC. STUD. OF SCI. (forthcoming 2007) [hereinafter Kahn, Exploiting Race];
Kahn, Racial Categories, supra note 8, at 24-28.
59. Press Release, U.S. Food & Drug Admin., FDA Approves BiDil Heart Failure
Drug for Black Patients (June 23, 2005), http://www.fda.gov/bbs/topics/NEWS/2005/
NEW01190.html.
60. See Kahn, Racial Categories, supra note 8, passim.
61. U.S. Patent No. 6,465,463 (filed Sept. 8, 2000) (issued Oct. 15, 2002), available at
http://www.uspto.gov/patft/index.html (search issued patents for "6,465,463"); Kahn, Racial
Categories, supra note 8, at 32.
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of heart disease. 6' By granting such a patent, the Patent and Trademark
Office ("PTO") is not only spurring innovation, it is also giving the
imprimatur of the federal government to the use of race as a genetic
category. 6' All indications seem to show that the drug is highly effective at
treating heart failure, 64 but the data underlying the FDA approval provides
no evidence that the drug works differently, or better, in African Americans
than in anyone else.65 The implications of using race to obtain patent
66protection and drug approval have only begun to be explored.
The racialization of patent law can only fully be understood when
viewed in relation to broader federal initiatives that shape the production
and use of racial categories in biomedical research. Recent debates over the
appropriate use of racial and ethnic categories in biomedical contexts have
concentrated largely on the practices of individual researchers with the aim,
in part, to help researchers appreciate the nuances and complexities of the
67racial categories they use and to treat racially coded data with greater care.
A focus on individual practices, while necessary, overlooks the myriad
structural forces that teach researchers and clinicians to see and use race in
particular and often problematic ways. Prominent among these forces are a
wide array of federal mandates that dictate the characterization and
application of genetically based biomedical interventions, such as
pharmaceuticals and diagnostic tests, in relation to socially defined
categories of race. Key federal mandates include: the NIH Revitalization Act
of 1993,68 which directs the National Institutes of Health to establish
guidelines for including women and minorities in clinical research; the
Food and Drug Administration Modernization Act of 1997,69 which, in the
context of drug development, directs that "the Secretary [of Health and
Human Services] shall, in consultation with the Director of the National
Institutes of Health and with representatives of the drug manufacturing
62. Kahn, Racial Categories, supra note 8, at 18.
63. Id. at 33.
64. Anne L. Taylor et al., Combination of Isosorbide Dinitrate and Hydralazine in Blacks with
Heart Failure, 351 NEW ENG.J. MED. 2049, 2049-57 (2004).
65. Pamela Sankar & Jonathan Kahn, BiDil: Race Medicine or Race Marketing, HEALTH
AFFAIRS, Oct. 11, 2005, at W5-455, available at http://content.healthaffairs.org/
cgi/content/full/hlthaff.w5.455/DC1.
66. See, e.g., Kahn, Racial Categories, supra note 8, passim.
67. See, e.g., Esteban Gonzdlez Burchard et al., The Importance of Race and Ethnic Background
in Biomedical Research and Clinical Practice, 348 NEW ENG. J. MED. 1170, 1170-75 (2003); Richard
S. Cooper et al., Race and Genomics, 348 NEW ENG.J. MED. 1166, 1166-70 (2003); Elizabeth G.
Phimister, Medicine and the Racial Divide, 348 NEW ENG. J. MED. 1081, 1081-82 (2003); Pamela
Sankar & Mildred K. Cho, Genetics: Toward a New Vocabulary of Human Genetic Variation, 28
SCIENCE 1337, 1337-38 (2002).
68. NIH Revitalization Act of 1993, Pub. L. No. 103-43, 107 Stat. 122 (codified as amended
in scattered sections of 42 U.S.C.).
69. Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, 111
Stat. 2296 (codified as amended in scattered sections of 21 U.S.C.).
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industry, review and develop guidance, as appropriate, on the inclusion of
women and minorities in clinical trials"70 ; and two subsequent Food and
Drug Administration Guidances for Industry. The first, a 1999 guidance
entitled "Population Pharmacokinetics," 71 made recommendations on the
use of population pharmacokinetics in the drug-development process to
help identify differences in drug safety and efficacy among population
subgroups, including race and ethnicity. 72 The second, a 2005 guidance
entitled "Collection of Race and Ethnicity Data in Clinical Trials,"
73
recommends a standardized approach for collecting and reporting race and
ethnicity information in clinical trials that produce data for applications to
the FDA for drug approval.74
Structuring the classification in each of these mandates is the Office of
Management and Budget's Revised Directive 15 on "Standards for
Maintaining, Collecting, and Presenting Federal Data on Race and
Ethnicity."75 The standards were developed "to provide a common language
for uniformity and comparability in the collection and use of data on race
and ethnicity by Federal agencies."76 The directive sets forth the following
basic racial categories for organizing such data: American Indian or Alaska
Native, Asian, Black or African American, Native Hawaiian or Other Pacific
Islander, and White.77 There are two categories for data on ethnicity:
"Hispanic or Latino," and "Not Hispanic or Latino.
"
0
s
These federal mandates have a profound effect upon the use of racial
categories in biomedical research, clinical practice, product development,
and health policy.79 By conditioning grants and approvals on the collection
of data according to the OMB categories, they provide incentives to
introduce race into biomedical contexts, regardless of its relevance."s Once
in circulation, racial categories can take on a life of their own and may be
exploited in new and unanticipated ways, with unforeseen and potentially
harmful consequences.
70. Id. § 115.
71. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: POPULATION P-ARMACOKINETICS
(1999) [hereinafter FDA, POPULATION PHARMACOKINETICS], available at http://www.fda.gov/
cder/guidance/1852fnl.pdf.
72. Id.
73. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: COLLECTION OF RACE AND ETHNICITY
DATA IN CLINICAL TRIALS (2005), available at http://www.fda.gov/cder/
guidance/5656fnl.htm.
74. Id.
75. OMB, Revisions, supra note 28.
76. Id.
77. Id.
78. Id.
79. See, e.g., Symposium on Race/Ethnicity and the 2000 Census, 90 AM. J. PUB. HEALTH 1687-
1781 (2000).
80. Id.
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The strategic commercial mobilization of race and ethnicity in the
context of biotechnology patents is not merely coincidental with the
proliferation of new genetic knowledge. Federal initiatives have played a
central role in producing, classifying, and disseminating human genetic• • 81
information. Once race is conceptualized in relation to biotechnology
products, the patent system itself provides incentives for using race and
ethnicity in order to maximize a patent's scope, duration, and viability.
82
Federal initiatives, guidelines, and approvals thus provide specific, targeted
incentives to recognize and use race and ethnicity in relation to
biotechnological innovation in a manner that promotes, indeed rewards, the
reification of race as a genetic category.
III. PRODUCING AND ORGANIZING SOCIAL DATA ON RACE AND ETHNICITY:
OMB DIRECTivE 15
The U.S. government has long collected data based on categories of
race and ethnicity.s3 The census is a prime example. Since the first census in
1790, racial categories have changed over time to reflect the social and
political concerns of the day. The first census had four categories: Free
White Male, Free White Female, Other Free Person, and Slave.8 4 During the
nineteenth century, additional categories that fell in and out of use
included: Free Colored Person, Black, Mulatto, Quadroon, Octoroon,
Indian, Chinese, and Japanese. 85 The twentieth century saw a new
proliferation of categories, including Hindu, Korean, and Negro. 6 Then, in
the 1970s, various federal agencies responsible for collecting data relating to
race and ethnicity beyond the census, led by the Office of Education and the
Department of Health, Education, and Welfare, came to the OMB looking
for assistance in developing government-wide standards for data on race and
ethnicity.
7
In 1977, the OMB produced "Statistical Policy Directive No. 15, Race
and Ethnic Standards for Federal Statistics and Administrative Reporting."88
After several revisions and much debate over the following two decades,
81. See infra text accompanying notes 99-151.
82. See infra text accompanying notes 213-46.
83. MELISSA NOBLES, SHADES OF CITIZENSHIP: RACE AND THE CENSUS IN MODERN POLITICS
28 (Stanford University Press 2000).
84. Id.
85. Id. at 28, 44.
86. Id. at 44. See generally MARGOJ. ANDERSON, THE AMERICAN CENSUS: A SOCIAL HISTORY
(Yale University Press 1988) (discussing the history of the U.S. Census).
87. NOBLES, supra note 83, at 79-84; see also Alice Robbin, Classifying Racial and Ethnic
Group Data in the United States: The Politics of Negotiation and Accommodation, 27J. GOV'T INFO. 129,
133 (2000) [hereinafter Robbin, Classifying].
88. Standards for the Classification of Federal Data on Race and Ethnicity, 59 Fed. Reg.
29,831, 29,831 (June 9, 1994), available at http://www.whitehouse.gov/omb/fedreg/
notice_15.html.
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Directive 15 now provides the following categories as a minimum standard
for maintaining, collecting, and presenting data on race and ethnicity for all
federal-reporting purposes: American Indian or Alaska Native; Asian; Black
or African American; Hispanic or Latino; Native Hawaiian or Other Pacific
Islander; and White.89 Beyond this minimum standard, agencies and
researchers have some latitude as to specifically how they will use the
categories. Thus, for example, in the 2000 Census, the Census Bureau
allowed individuals to self-identify and to select multiple categories of
race/ethnicity.90
The power of the OMB data standards to affect our understanding of
identity and group status is profound. As a consequence of major
governmental programs and legal initiatives instituted since the 1960s, the
OMB standards provide the basis both for census information and also for
access to a variety of governmental goods and services that are contingent
upon falling into a particular racial or ethnic group.9' For example, federal
users of racial data provided by the census include: Department of
Education, Department ofJustice, Department of Labor, Equal Employment
Opportunity Commission, Federal Reserve, Department of Health and
Human Services, Housing and Urban Development, Department of• 92
Agriculture, and Veterans Administration. Alice Robbin notes, "[g]roups
must be counted in order to make credible claims for political
representation, demonstrate discriminatory practices against them, seek and
obtain legal remedies, receive governmental assistance for a host of social
programs, and evaluate current, as well as develop new, public policy."9 '
Additionally, they provide the framework for evaluating school
desegregation, electoral districting, and other civil rights initiatives.94 It is in
this context that federal initiatives have created a new possessive interest in
hitherto marginalized and subordinated racial identities. The OMB
categories (as a basis for classifications used in the census and other areas)
89. OMB, Revisions, supra note 28; see also U.S. Census Bureau, Racial and Ethnic
Classifications Used in Census 2000 and Beyond (Apr. 12, 2000), http://www.census.gov/
population/www/socdemo/race/racefactcb.html.
90. NOBLES, supra note 83, at 81-84; see also U.S. Census Bureau, supra note 89; Katherine
K. Wallman et al., Measuring Our Nation's Diversity: Developing a Common Language for Data on
Race/Ethnicity, 90 AM.J. PUB. HEALTH 1704,1705 (2000).
91. NOBLES, supra note 83, at 75-79.
92. U.S. Census Bureau, supra note 89.
93. Alice Robbin, The Politics of Representation in the U.S. National Statistical System: Origins of
Minority Population Interest Group Participation, 27J. GOV'T INFO. 431, 435 (2000); see also Robbin,
Classifying, supra note 87, at 149.
94. See Michael Omi, Racial Identity and the State: The Dilemmas of Classification, 15 LAW &
INEQ. 7, 10, 13 (1997); Robbin, Classifying, supra note 87, at 148-50.
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have also shaped individuals' conceptions of their very identity as
Americans.95
In the context of state public health practice, several authors note that
"[a]lthough the revised OMB standards do not explicitly affect state and
local public health agencies, their impact will in fact be profound. Many
core state public health data sets . . . are implemented through federal
funds, and they will be expected to meet the revised OMB standards."9 6 The
same may be said of all federally funded research and practice that touches
on health-related issues. As Michael Omi observes, "Directive 15 has become
the de facto standard for state and local agencies, the private and nonprofit
sectors, and the research community."97 This dynamic reinforces what Omi
characterized as an "interesting dilemma" facing scientists in the United
States: "On the one hand," Omi asserts, "scientists routinely use racial
categories in their research and regularly make comparisons between races
with respect to health.... On the other hand, many scientists feel that racial
classifications are meaningless and unscientific."
9 8
IV. PRODUCING AND ORGANIZING GENETIC INFORMATION:
FEDERALLY SPONSORED GENETIC DATABASES
This dilemma is likely to become even more problematic as biomedical
researchers and clinicians use the social categories of race mandated by
OMB Directive 15 alongside purported genetic population groupings
produced and organized by federally sponsored genomic initiatives. As
genetic research has grown over the past three decades, the federal
government has sponsored an array of data banks that collect, store, and
classify genetic information for use by biomedical researchers. Such data
banks include the National Institute of General Medical Sciences
("NIGMS")-Coriell Human Genetic Variation Collections,99 the DNA
Polymorphism Discovery Resource ("PDR"),' 00 the dbSNP database,'0 ' and
95. See generally NOBLES, supra note 83 (exploring the politics of race, census, and
citizenship); Omi, supra note 94; Robbin, Classifying, supra note 87.
96. Daniel J. Friedman et al., Race/Ethnicity and OMB Directive 15: Implications for State Public
Health Practice, 90 AM.J. PUB. HEALTH 1714, 1714-19 (2000); see also Nancy Krieger, Counting
Accountably: Implications of the New Approaches to Classifying Race/Ethnicity in the 2000 Census, 90
AM. J. PUB. HEALTH 1687, 1687-89 (2000); Edward Sondik et al., Race/Ethnicity and the 2000
Census: Implications for Public Health, 90 AM.J. PUB. HEALTH 1709,1709-13 (2000); id. at 1714-19
(discussing the possible impact of the Directive).
97. Omi, supra note 94, at 21.
98. Id. at 7.
99. NIGMS, Human Variation Collections of the NIGMS Repository,
http://locus.umdnj.edu/nigms/cells/humdiv.html (last visited Sept. 19, 2006).
100. NIGMS, DNA Polymorphism Discovery Resource, http://locus.umdnj.edu/
nigms/products/pdr.html (last visited Sept. 19, 2006).
101. National Center for Biotechnology Information, Single Nucleotide Polymorphism,
http://www.ncbi.nlm.nih.gov/SNP/popcass.cgi (last visited Sept. 19, 2006).
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the International Haplotype Map Project (also known as the "HapMap"). 1°2
Acting as an umbrella over these collections is a repository maintained by
the federal government's National Center for Biotechnology Information
("NCBI"), known as "GenBank," which contains a web-based annotated
collection of all publicly available DNA sequences.13 GenBank, in turn, is
part of the International Nucleotide Sequence Database Collaboration,
which includes the DNA DataBank of Japan ("DDBJ"), the European
Molecular Biology Laboratory ("EMBL"), and GenBank at NCBI. 10 4 Each of
these databases organizes genetic information into highly problematic
population groupings that are adapted and used by researchers as correlates
for racial categories.' ° 5 These databases are not only powerful because of
their method of internally categorizing genetic information, but also
because, as examples of authoritative scientific research, they provide
working models of acceptable categorization by which any scientist may
organize genetic data.
Maintained by the independent, non-profit Coriell Institute for Medical
Research, the NIGMS "Human Genetic Cell Repository" aims to provide
"scientists with the materials for accelerating disease-gene discovery.' 06 As
organized in its Human Genetic Variation Collection, the NIGMS
classification of genetic data includes the following "Population" groups:'07
102. NHGRI, Developing a Haplotype Map of the Human Genome for Finding Genes
Related to Health and Disease, http://www.genome.gov/10001665 (last visited Sept. 19, 2006)
[hereinafter HapMap].
103. National Center for Biotechnology Information, . GenBank Overview,
http://www.ncbi.nlm.nih.gov/Genbank/index.html (last visited Sept. 19, 2006).
104. Id.
105. See infra text accompanying notes 106-51.
106. NIGMS, NIGMS Human Genetic Cell Repository, http://locns.umdnj.edu/nigms/
(last visited Sept. 19, 2006).
107. Coriell Institute for Medical Research, Human Genetic Variation Collections of the
NIGMS Repository, http://locus.timdnj.edu/nigms/cells/humdiv.html (last visited Jan. 7,
2006).
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Human Variation Collections of the NIGMS Repository
North American/Caribbean Europe Asia/Pacific
* African Americans * Basque * Aboriginal Tribe from Taiwan
(Ami)
* Caucasians * Czechoslovakian * Aboriginal Tribe from Taiwan
(Atayal)
* Han People of Los Angeles * Greek * Chinese
* Mexican American Community * Hungarian Indo Pakistani
of Los Angeles
* Caribbean Iberians * Japanese
* Mayan - Campeche State of the * Iceland * Khmer - Cambodia
Yucatan
* Mexican * Italian * Melanesian - Bougainville in the
Solomon Islands
* Mexican Indian * Northern European * Pacific
* Puerto Rican * Russian - Krasnodar in southeast e Southeast Asians (excluding
European Russia Japanese and Chinese)
Russian - Zversky District
northeast of Moscow
South America Africa
* Karitiana - Rondonia Province * Africans North of the Sahara
of Brazil
* Quechua - South Central Andes * Africans South of the Sahara
of Peru
* South America (Andes) * Biaka - Bagandu in the Central
African Republic
* South America (Brazil, Guyana, * Mbuti - Ituri Forest in northeast
and Venezuela) Zaire
Surui - Rondonia Province of
Brazil
Middle East
* Ashkenazi Jewish
* Druze - a community from
northern Israel
* Middle Eastern (Version 1)
* Middle Eastern (Version 2)
* Waorani - Auca Indian from
Ecuador
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As a comprehensive database, the NIGMS collection also includes access to
data from the PDR, dbSNP, and the International HapMap Project. It
classifies genetic samples according to a wide array of categories that freely
mix race, ethnicity, religion, geography, and citizenship-implying that each
has distinctive and legitimate relations to genetic variation.
The PDR is maintained by the National Human Genome Research
Institute ("NHGRI"), in collaboration with the Centers for Disease Control
and Prevention ("CDC") and the NIGMS.10 This resource is "comprised of
cell lines and DNA samples from 450 unrelated individuals, male and
female. It is designed to reflect the diversity in the human population....
The individuals sampled include European-Americans, African-Americans,
Mexican-Americans, Native Americans, and Asian-Americans. " 1°9
The NHGRI and the National Center for Biotechnology Information
maintain the publicly accessible dbSNP database of single nucleotide
polymorphisms ("SNPs")."o The dbSNP database contains information on
more than 2.7 million SNPs that researchers use to explore the structure of
human variation and to design genetic association studies.111 The database
groups its genetic data into the following categories:' 12
108. Coriell Institute for Medical Research, Polymorphism Discovery Resource,
http://locus.umdnj.edu/nigms/products/pdr.html (last visitedJan. 7, 2006).
109. Id.
110. A SNP is a DNA sequence variation that occurs when a single nucleotide (A, T, C, or
G) in the genome sequence is altered. MERRIAM-WEBSTER ONLINE DICTIONARY, http://www.m-
w.com/dictionary/snp (last visited Sept. 19, 2006). Each individual has many SNPs that
together create a unique DNA pattern for that person. SNPs promise to significantly advance
our ability to understand and treat human disease.
111. See generally Noah A. Zaitlen et al., Inference and Analysis of Haplotypes from Combined
Genotyping Studies Deposited in dbSNP, 15 GENOME RES. 1594 (2005).
112. National Center for Biotechnology Information, supra note 101.
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Class Tag
Central Asia
Central/South
Africa
Central/South
America
East Asia
Europe
Multi-National
North America
North/East Africa
& Middle East
Pacific
Unknown
West Africa
Description
Samples from Russia and satellite Republics,
Nations bordering Indian Ocean between East
Asia and Persian Gulf regions.
Nations south of Equator, Madagascar &
neighboring Island Nations.
Samples from Mainland Central and South
America, Island Nations of western Atlantic,
Gulf of Mexico and Eastern Pacific.
Samples from Eastern and South Eastern
Mainland Asia, Northern Pacific Island
Nations.
Samples from Europe north and west of
Caucasus Mountains, Scandinavia, Atlantic
Islands.
Samples that were designed to maximize
measures of heterogeneity or sample human
diversity in a global fashion. Examples
OEFNERIGLOBAL and CEPH repository.
All samples north of Tropic of Cancer. This
would include defined samples of U.S.
Caucasians, African Americans and Hispanics,
and NCBIINIHPDR.
Samples collected from North Africa
(including Sahara desert), East Africa (south
to Equator), Levant, Persian Gulf.
Samples from Australia, New Zealand, Central
and Southern Pacific Islands, Southeast Asian
Peninsular/Island Nations.
Samples with unknown geographic
provenience that are not global in nature.
Sub-Saharan Nations bordering Atlantic north
of Congo River, and Central/Southern
Atlantic Island Nations.
Total
SNP Count (RS)
564
1833
317731
11145
326853
324289
28
3574
92670
3680
1082476
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Like the NIGMS/Coriell collection, these crude categories employ racial
and ethnic constructs (e.g., U.S. Caucasians, African Americans, and
Hispanics), geographic constructs (e.g., North Africa, East Africa), political
nation states (e.g., Russia and Satellite republics), mixes of geography and
nation states (e.g., Sub-Saharan Nations bordering the Atlantic North of the
Congo River), and mixes of all three ("All samples north of Tropic of
Cancer. This would include defined samples of U.S. Caucasians, African
Americans and Hispanics."). '" 3 Thus, as biomedical researchers mine the
dbSNP data, they are accessing and organizing terms that juxtapose or
directly classify genetic data in terms of race, ethnicity, nation, and/or
geography. When used in studies or trials covered by federal mandates, the
diverse and sometimes contradictory population classifications employed
variously by the NIGMS, PDR, and dbSNP databases cry out to be simplified
and reclassified in terms of the basic OMB Directive 15 social categories of
race and ethnicity.
A potentially different, but still problematic model of federally
sponsored genetic database production and organization, is the
International HapMap Project. The Project is premised on a recognition
that identifying the significance of each individual SNP would be a daunting
task because there is approximately one SNP for every 1,000 bases of DNA,
with an estimate of perhaps 4 million common SNPs. 1 4 Recent research has
found, however, that SNPs travel across generations in rather large blocks,
often 10,000 to 50,000 nucleotide bases each." 5 These blocks are known as
haplotypes.1 6 The SNPs located in such haplotypes tend to group in a
limited number of variants. 1 7 Thus, for a particular block of bases along a
chromosome, there may be only four or five different haplotypes for 80% or
90% of the population.' 8 Each haplotype thus contains significantly more
information than individual, unorganized SNPs. The International
Haplotype Map Project aims to show the haplotype blocks and the SNPs that
define them. 19 This grouping of SNPs into haplotypes promises to increase
greatly the efficiency of genetic research by enabling scientists to search
through bundles of 10,000 to 50,000 bases rather than going through an
entire genome one base at a time to discover specific SNPs. 20 Thus,
haplotyping promises to be a significant tool for establishing the genetic
113. See generally id.
114. See HapMap, supra note 102.
115. MarkJ. Daly et al., High Resolution Haplotype Structure in the Human Genome, 29 NATURE
GENETICS 229, 229-32 (2001); Laura Helmuth, Map of the Human Genome 3.0, 293 SCIENCE 583,
583-85 (2001).
116. HapMap, supra note 102.
117. Id.
118. Helmuth, supra note 115, at 584.
119. HapMap, supra note 102.
120. Id.
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bases of susceptibility to certain diseases, 12 1 vulnerability to environmental
toxins, and drug metabolism and response.
In an article published in the journal Nature in November 2005, the
International HapMap Consortium announced the completion of Phase I of
its project. This phase catalogued more than one million SNPs in the
genome sequences of 269 people who were classified into four population
groups: "(1) 90 individuals . . .from the Yoruba in Ibidan, Nigeria ... ;
(2) 90 individuals .. . in Utah, USA... ; (3) 45 Han Chinese in Beijing,
China .. . ; [and] (4) 44 Japanese in Tokyo, Japan." 123 In contrast to the
population categories in other federally sponsored genetic databases, the
Consortium was careful to emphasize that:
[B]ecause none of the samples was collected to be representative of
a larger population such as 'Yoruba,' 'Northern and Western
European', 'Han Chinese', or 'Japanese', (let alone all the
populations from 'Africa', 'Europe', or 'Asia'), we recommend
using a specific local identifier (for example, 'Yoruba in Ibidan,
Nigeria') to describe samples initially.1
24
And indeed, the samples subsequently deposited with the NIGMS/Coriell
Human Genetics Variation Collection are so identified.125 This unusually
careful characterization of data results, in part, from the Consortium's
deliberate attention to what it termed "[i]ntegrating [e]thics and [s]cience
in the International HapMap Project."
26
Yet, as the data from the HapMap has been taken up and circulated
both in the popular press and in scientific journals, these careful
classifications have already been conflated with the broad, racially marked
continental categories of "African," "Asian," and "European." For example,
prominent popular reports of the completion of the first phase of the
HapMap described the samples variously as "people from Africa, the Far
East, and western Europe";12 7 "people from Asia, Africa and the United
States";12 8 and "individuals from Africa, Asia, and the United States, which
121. Dalyetal., supranote 115, at 229-30.
122. See generally Helmuth, supra note 115, at 583-84; HapMap, supra note 102.
123. International HapMap Consortium, A Haplotype Map of the Human Genome, 437 NATURE
1299, 1300 (2005) [hereinafter IHC2005].
124. Id.
125. Coriell Institute for Medical Research, Human Variation Collections of the NIGMS
Respository, http://ccr.coriell.org/nigms/cells/humdiv.html (last visited Sept. 19, 2006).
126. International HapMap Consortium, Integrating Ethics and Science in the International
HapMap Project, 5 NATURE REVIEWS GENETICS 467,467-75 (2004) [hereinafter IHC2004].
127. BBC News, Gene Map Points to Personal Drugs, Oct. 26, 2005, http://news.bbc.co.uk/
1/hi/health/4378624.stm.
128. Patricia Reaney, Scientists Complete Map of Human Genetic Variation, BOSTON GLOBE, Oct.
26, 2005, available at http://www.planetark.com/avantgo/dailynewsstory.cfm?newsid=33188.
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represented the European population. "1 29 Among scientific journals, a
recent typical article on linkage disequilibrium in the American Journal of
Human Genetics refers to the HapMap as sampling "four populations with
African, Asian, and European ancestry."
130
The IHC itself bears a measure of responsibility for such easy
conflation. The initial justification for selecting geographically dispersed
populations was to capture greater variation.' But one could argue that
since the greatest genetic diversity is to be found among populations within
Africa, i1 2 a more revealing map might have been developed by sampling
geographically dispersed populations within Africa. Alternatively, the IHC
could have chosen not to mark the samples according to their points of
origin. Moreover, in its actual sampling and classification strategy, the IHC
sent conflicting messages regarding the local specificity of the populations.
Most prominently, in sampling forty-five Han Chinese and forty-four
Japanese, the project design implicitly asks for these two groups to be
amalgamated into a larger "Asian" category to parallel the ninety samples
each from the Ibidan, Nigeria, and Utah collections. The IHC's otherwise
responsible and careful post-hoc characterization of the samples thus
operates in tension with the message sent by the underlying structure of the
project design.
All of these genetic databases are state-sponsored technologies of
classification. They provide means to organize a vast array of genetic
information into more comprehensible and usable forms. The HapMap, in
particular, promises more rapid and efficient analysis of genetic variation
through classification by haplotype mapping that may enhance the
identification of polymorphisms that correlate to particular diseases and
susceptibilities.13 3  It also may provide the basis for advances in
pharmacogenomics and the development of personalized medicines tailored
to an individual's genotype.134
Systems of classification, however, are artifacts that embody ethical
choices. As Bowker and Star note, "each standard and each category
valorizes some point of view and silences another. This is not inherently a
bad thing-indeed it is inescapable. But it is an ethical choice, and as such it
129. Ronald Kotulak, Genetic Map Points Way to Root of Disease, STAR-LEDGER (Newark, N.J.),
Oct. 27, 2005.
130. J.C. Mueller et al., Linkage Disequilibrium Patterns and tagSNP Transferability Among
European Populations, 76 AM.J. HUM. GENETICS 387, 388 (2005).
131. IHC2004, supra note 126; IHC2005, supra note 123.
132. L. Jorde et al., The Distribution of Human Genetic Diversity: A Comparison of Mitochondrial,
Autosomal, and Y-Chromosome Data, 66 AM.J. HUM. GENETICS 979, 983 (2000).
133. IHC2004, supra note 126, at 467.
134. Id.; see Sandra Lee, Racializing Drug Design: Implications of Pharmacogenomics for Health
Disparities, 95 AM.J. PUB. HEALTH 2133, 2135 (2005).
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is dangerous-not bad, but dangerous."' 35 In the realm of genetics, where
such systems address the human body, new biologically based categories can
affect profoundly people's identities, aspirations, and dignity. Genetic
classification is powerful, but it is also dangerous because it involves
biological categories that may be confused and conflated with race. Any
resulting reification of social categories of race as biological constructs risks
new forms of exclusion and stigma.1
36
In a different but related context, Bowker and Star note how
psychiatrists increasingly use the language of the Diagnostic and Statistical
Manual ("DSM") "to communicate with each other and their accounting
departments, although they frequently do not believe in the categories they
are using."137 It is unlikely that scientists and other professionals "do not
believe" in the biological categories they use when developing and
employing information from genetic databases. However, for many federally
funded researchers and practitioners who use genetic information, the
government mandates the collection and organization of biological data
according to socially constructed categories of race and ethnicity.3 8 Like
psychiatrists using the DSM, researchers who might not otherwise believe in
any biological basis for race may easily default to using racial categories in
biological contexts, especially when directed by federal mandate.1
3 9
Certain health effects do correlate with social categories of race and
ethnicity, and scientists may legitimately use the collection of health data
according to these categories, so long as the categories are understood as
social and not genetic. 140 In the field of public health research in particular,
racial and ethnic data play a central role in developing policies and
interventions to combat inequities in the delivery of health care. 141 Thus, for
example, Stephen Thomas argues that "to adequately address racial and
135. GEOFFREY C. BOWKER & SUSAN LEIGH STAR, SORTING THINGS OUT: CLASSIFICATION AND
ITS CONSEQUENCES 5-6 (1999).
136. See, e.g., TROY DUSTER, BACKDOOR TO EUGENICS passim (2d ed. 1990); Kahn, Racial
Categories, supra note 8, at 33-42; Lock, supra note 41, at 84-89; Morris W. Foster,
Nat'l Human Genome Research Inst., Ethical Issues in Developing a Haplotype Map
with Socially-Defined Populations, http://www.nhgri.nih.gov/About.NHGRI/Der/haplotype/
haplotypeELSI.html (last visited Sept. 19, 2006).
137. BOWKER& STAR, supra note 135, at 4.
138. See supra text accompanying notes 67-78.
139. See supra text accompanying notes 91-98.
140. See, e.g., Stephen B. Thomas, The Color Line: Race Matters in the Elimination of Health
Disparities, 91 AM. J. PUB. HEALTH 1046, 1046-48 (2001); U.S. DEP'T OF HEALTH & HUMAN
SERVICES, OFFICE OF THE CHIEF INFO. OFFICER, HHS POLICY FOR IMPROVING RACE AND ETHNICITY
DATA (1997), http://hhs.gov/oirm/infocollect/nclusion.html, in IMPROVING THE COLLECTION
AND USE OF RACIAL AND ETHNIC DATA IN HHS: JOINT REPORT OF THE HHS DATA COUNCIL
WORKING GROUP ON RACIAL AND ETHNIC DATA AND THE DATA WORK GROUP OF THE HHS
INITIATIVE TO ELIMINATE RACIAL AND ETHNIC DISPARITIES IN HEALTH (1999), available at
http://aspe.os.dhhs.gov/datacncl/RaceRpt/index.htm (follow link to Appendix G).
141. Thomas, supra note 140, at 1046-47.
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ethnic health disparities, we need data that include race as a variable, even if
race cannot be defined precisely .... Without racial/ethnic data we cannot
monitor progress or setbacks in addressing racial/ethnic inequalities in
health." 42 Indeed, one of the primary goals of the federal government's
"Healthy People 2010" initiative is "to eliminate health disparities among
different segments of the population."'143 Thus, an ongoing tension exists
between the need to resist the reductive tendency to naturalize race as a
genetic category and the practical reality that race, as a social category, may
end up influencing levels of stress, access to care, or other aspects that have
biological consequences that need to be addressed.
Addressing the conundrum of race in biomedical contexts, Troy Duster
argues that "we should recognize, engage, and clarify the complexity of the
interaction between any taxonomies of race and biological,
neurophysiological, social and health outcomes" and urges that in some
cases "we must conduct systematic investigations, guided by theory, into the
role of the interaction of race (or ethnicity or religion)-however flawed as
a biologically discrete and coherent taxonomic system-with feedback loops
into the biological functioning of the human body, and then again in
relation to medical practice."144 The circulation of OMB Directive 15
categories and federally managed genetic databases also reveals how state
initiatives are deeply embedded in the construction and maintenance of
such "feedback loops." One's race may affect one's health. 45 As race affects
biology, it becomes inextricably linked to biology. But this is not the same
thing as saying race has a genetic basis. Nonetheless, as mandates for the
collection of clinical data using socially constructed racial categories
produce information that may be interpreted with reference to genetic data,
this, in turn, is classified with reference to social categories.
The community of natural and social scientists at large, including key
scientific journals, generally has embraced the notion that race has no
essential genetic basis. 14 6 Nonetheless, this remains a fairly abstract
recognition. In practice, even thoughtful scientists, clinicians, and medical
professionals may casually refer to "race" as a crude proxy for descent
142. Id. at 1047.
143. U.S. Dep't of Health & Human Servs., Office of Disease Prevention & Health
Promotion, Healthy People: What Are Its Goals, http://www.health.gov/healthypeople/
About/goals.htm (last visited Sept. 19, 2006).
144. Duster, supra note 39, at 258-59, 272-73.
145. See generally INST. OF MED., UNEQUAL TREATMENT: CONFRONTING RACIAL AND ETHNIC
DISPARITIES IN HEALTH CARE (2003).
146. See generally CRITICAL RACE THEORY: THE CONCEPT OF "RACE" IN NATURAL AND SOCIAL
SCIENCE (Nathaniel E. Gates ed., 1997); Collins, supra note 38, at S13-15 (2004); Editorial,
Census, Race and Science, 24 NATURE GENETICS 97, 97-98 (2000); AAA, Response, supra note 43;
AAA, Statement, supra note 43; Int'l Comm. of Med. Journal Editors (ICMJE), Uniform
Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical
Publication (2001), available at http://www.icmje.org/.
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population or more generally as if it had some other essential genetic
meaning. Omi observes with respect to the social sciences that "much of
sociological research, though firmly committed to a social as opposed to
biological interpretation of race, nevertheless slips into a kind of objectivism
about racial identity and racial meaning. . . . Although abstractly
acknowledged to be a sociohistorical construct, race in practice is often
treated as an objective fact.' 47 Moreover, as Alan Goodman notes, "during
the past decade, racialized notions of biology have made a comeback."1
48
As scientists and health professionals increasingly use federally
maintained genetic-population categories alongside the federally mandated
social categories of race and ethnicity, these two powerful systems of
categorization are colliding in practice and becoming confused in everyday
discourse, with consequences that are difficult to foresee. 149 Like the
psychiatrists who use DSM categories they do not believe in, the power of
social categories to shape scientific and professional practice is leading to
the convenient use of racial and ethnic categories in inappropriate and
harmful ways.150
Bowker and Star argue that:
[P] olitically and socially charged agendas are often first presented
as purely technical and they are difficult even to see. As layers of
classification system become enfolded into a working
infrastructure, the original political intervention becomes more
and more firmly entrenched. In many cases, this leads to a
naturalization of the political category .... It becomes taken for
granted.
5 1
Genetic databases and OMB Directive 15 are seemingly "technical" methods
of categorization, but such apparent neutrality is precisely what drives and
lends the aura of legitimacy to the casual and often reflexive conflation of
race and genetics in a variety of biomedical contexts.
147. Omi, supra note 94, at 21.
148. Alan Goodman, Why Genes Don't Count (for Racial Differences in Health), 90 AM. J. PUB.
HEALTH 1699, 1699 (2000).
149. Jonathan Kahn, Genes, Race, and Population: Avoiding a Collision of Categories, 96 AM. J.
PUB. HEALTH 1965 (2006) [hereinafter Kahn, Genes, Race, and Population).
150. See, e.g., Kahn, Racial Categories, supra note 8, at 4 (offering recommendations,
"including that the Federal government must develop guidelines . . . to distinguish the use of
race as a socio-political category... from the use of race as a purportedly biological category");
Lee et al., supra note 13 (discussing the prevalence of racial categorization in genetics
research).
151. BoWKER & STAR, supra note 135, at 196.
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V. BIDIL: PORTENT OF THINGS TO COME
On June 23, 2005, the FDA formally approved the heart-failure drug
BiDil to treat heart failure in "self-identified black patients." 5 2 Widely hailed
throughout the media and professional journals as the first "ethnic" drug,
BiDil has become a focal point for debates over the appropriate use of racial
categories in biomedical research, drug development, and clinical
practice.
53
The FDA approval was based on results from A-HeFT, the African
American Heart Failure Trial, which were published the previous November
in the New England Journal of Medicine. 154 The trial design, approved by
the FDA, was itself path-breaking because it included only self-identified
African Americans. 1 The results therefore give the impression that BiDil
works only in African Americans. This is clearly not the case. The trial
investigators themselves concede that BiDil will work in people regardless of
race.15 6 Without a comparison population, the investigators cannot even
claim that the drug works differently in African Americans than in any other
group. Nonetheless, NitroMed, the corporate sponsor of BiDil, applied for
and received FDA approval for the drug with a race-specific indication to
treat heart failure only in African Americans.15 7 Pervasive media coverage of
the announcement of the results and the FDA approval has also focused on
the racial specificity of the drug, often explicitly claiming that this showsS • 158
race is genetic.
Underlying the trial design, however, is a race-specific patent that is
premised on a biological or genetic conception of race. 159 The PTO issued
the patent on October 15, 2002.' 60 It confers intellectual property protection
for the method of using the drug to treat heart failure in African Americans
152. Press Release, Food & Drug Admin., FDA News, FDA Approves BiDil Heart Failure
Drug for Black Patients (June 23, 2005), available at http://www.fda.gov/bbs/
topics/NEWS/2005/NEW01190.html.
153. Kahn, Disparity, supra note 9, at 105-08.
154. See generally Taylor et al., supra note 64.
155. A-HeFT.org, Questions About the A-HeFT Study, http://www.aheft.org/questions.asp
(last visited Oct. 16, 2006).
156. For example, Jay Cohn, the original holder of BiDil's treatment-regimen patents, has
stated that he himself prescribes the generic combination to white patients who do not respond
well to other drugs and concluded, "I actually think everybody should be using it." Denise
Gellene, Heart Pill Intended Only for Blacks Sparks Debate, L.A. TIMES, June 16, 2005, available at
http://pqasb.pqarchiver.com/latimes/search.html (search for "Heart Pill Intended only for
Blacks Sparks Debate" in headline field).
157. Kahn, Disparity, supra note 9, at 105-06.
158. Jonathan Kahn, Letter to the Editor, Misreading Race and Genomics After BiDil, 37
NATURE GENETICS 655, 655-56 (2005) [hereinafter Kahn, Letter to the Editor]; Kahn, Racial
Categories, supra note 8, at 3, 22-25.
159. Sankar & Kahn, supra note 65, at W5-460-62.
160. U.S. Patent No. 6,465,463 (filed Sept. 8, 2000) (issued Oct. 15, 2002), available at
http://www.uspto.gov/patft/index.html (search issued patents for "6,465,463").
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until 2020.161 This is thirteen years longer than a previous patent issued in
1987 to the same inventor for the same method of using the same drug in
the general population without regard to race."6' In this case, bringing race
into the patent system allowed the inventor to gain a substantial extension of
his intellectual property monopoly. With a projected annual revenue stream
of $1-3 billion, the additional thirteen years amounts to a tremendous
windfall for NitroMed. 6 BiDil's race-specific patent provided the underlying
support that drove NitroMed's subsequent development of a race-specific
trial design,' 64 its campaign to raise capital (first through private venture
165funding and later through a public offering of stock in 2004), the
approach to the FDA for race-specific approval, 166 and its massive marketing
campaign to third-party payers, individual doctors, and the public at large.1
67
Both the patent' 6s and the drug trial for BiDil explicitly relate their race-
specific design to a search for genetic markers underlying the disease.' 69 On
the one hand, this reflects an approach, largely sanctioned by many in the
field of pharmacogenomics, of using race instrumentally as a surrogate to
get at underlying genetic variation that ultimately could be identified
without reference to race.17 On the other hand, for the foreseeable future,
it presents the immediate reality of race being used as a quasi-genetic
category to obtain patents and drug approval.
As Lee et al. noted, "[r]esearch utilizing race serves to 'naturalize' the
boundaries dividing human populations, making it appear that the
differences found reflect laws of nature. In fact, the use of race and ethnicity
in biomedical research is problematic because it is caught in a tautology,
both informed by, and reproducing, 'racialized truths.' 1 71 Such a dynamic
portends the potential reinvigoration of legally sanctioned race-based
discrimination by recasting particular aspects of race in terms of biological
161. Sankar & Kahn, supra note 65, atW5-458.
162. Method of Reducing Mortality Associated with Congestive Heart Failure Using
Hydralazine and Isosorbide Dinitrate, U.S. Patent No. 4,868,179 (filed Apr. 22, 1987) (issued
Sept. 19, 1989), available at http://www.uspto.gov/patft/index.html (search issued patents for
"4,868,179").
163. Sankar & Kahn, supra note 65, at W5-458.
164. Kahn, Racial Categories, supra note 8, at 8; Sankar & Kahn, supra note 65, at W5-457-58.
165. Kahn, Racial Categories, supra note 8, at 24; Sankar & Kahn, supra note 65, at W5-457-
58.
166. Jonathan Kahn, BiDil: False Promises, GENEWATCH, Nov.-Dec. 2005, at 6-9 [hereinafter
Kahn, False Promises], available at http://www.gene-watch.org/genewatch/articles/ 18-
6Kahn.html; Kahn, Racial Categories, supra note 8, at 1-2.
167. Kahn, Disparity, supra note 9, at 118-20; Kahn, Racial Categories, supra note 8, at 24-28;
Sankar & Kahn, supra note 65, at W5-459-60.
168. U.S. Patent No. 6,465,463 (filed Sept. 8, 2000) (issued Oct. 15, 2002), available at
http://www.uspto.gov/pafft/index.html (search issued patents for "6,465,463").
169. Taylor et al., supra note 64, at 2049-51.
170. Lee, supra note 54, at 387-90; Tate & Goldstein, supra note 57, at S34-36.
171. Lee et al., supra note 13, at55.
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difference. Such discrimination is unlikely to appear in the familiar forms of
the past. We should not expect to see direct segregation or exclusion of
entire racial groups from rights and benefits based on their being identified
as genetically different. Rather, subtler forms of differential treatment may
arise based on tenuous correlations between genetic difference and racial
groups; these correlations may lead to selective discrimination among those
groups that is justified by reference to underlying "real" genetic distinctions.
Harm may come, not from deliberate animus toward a particular group, but
from the nature of the questions asked. For example, from an A-HeFT
researcher's conception of heart failure as a "different disease"' 72 in Blacks,
the potential exists for misallocation of resources away from traditional-
population health measures directed at ameliorating identified health
disparities 7 and toward the development of race-specific drugs such as
BiDil.
174
Is BiDil an anomaly? In 2003, VaxGen, developer of the AIDSVax
vaccine for HLV/AIDS, made an abortive attempt to use a post hoc
retrospective analysis of racial subgroups to salvage its failed trial results. 75
Recent reports of race-specific trials for the cancer drug Iressa and the
cholesterol-lowering drug Crestor, among others, would seem to indicate
that BiDil is ushering in a new era of race-based medicine.'7 6 For its multi-
billion dollar cholesterol-lowering statin, Crestor, AstraZeneca is currently
conducting three race- or ethnic-specific clinical trials in African Americans,
South Asians, and Hispanics. 177 Crestor, the trade name for rosuvastatin, has
come under intense scrutiny regarding claims about its safety. 171 In March
2004, Dr. Sidney Wolf, the Director of Public Citizen's Health Research
Group, petitioned the FDA to withdraw Crestor from the market for safety
reasons. 7 9 At the height of the controversy over Crestor's safety, cardiologist
Keith Ferdinand (who also participated in A-HeFT) announced early results
from the ARIES (African American Rosuvastatin Investigation of Efficacy
172. Clyde Yancy, The Role of Race in Heart Failure Therapy, 4 CURRENT CARDIOLOGY REP. 218,
224 (2002); see also, David Rotman, Race and Medicine, Population Genomics Is Expanding Our
Knowledge of Human Diversity, TECH. REv., Apr. 2005, at 60-65, available at
http://www.technologyreview.com/read.article.aspx?id=14301&ch=biotech (analyzing the role
race should have in drug development).
173. See generally INST. OF MED., UNEQUAL TREATMENT: CONFRONTING RACIAL AND ETHNIC
DISPARITIES IN HEALTH CARE (2002).
174. Kahn, Disparity, supra note 9, at 125-29.
175. Jon Cohen, VaxGen's Sketchy Statistics, SCIENCENOW, Feb. 27, 2003, available at
http://sciencenow.sciencemag.org/cgi/content/full/2003/227/1.
176. Matthew Herper, Race-Based Medicine Arrives, FORBES, May 10, 2005, available at
http://www.forbes.com/technology/2005/05/10/cxmh_O509racemedicine.html.
177. Kahn, Disparity, supra note 9, at 120-21.
178. Id.
179. Letter from Sidney Wolfe, Director, Pub. Citizen Health Research Group, to Mark B.
McClellan, Comm., Food & Drug Admin. (Mar. 4, 2004), available at http://www.citizen.org/
publications/release.cfm?ID=7305.
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and Safety) trial the same day that Anne Taylor announced the A-HeFT
results. "0 It is interesting to note that in an AstraZeneca press release
presenting the ARIES data, Ferdinand emphasized that the trial showed
both the safety and efficacy of Crestor. s8 Later, Ferdinand reiterated that
the ARIES trial should "add [] to physicians' comfort level. It's an additional
study to show that Crestor is more effective and safe."" 2 One need not
question Dr. Ferdinand's sincerity to consider that AstraZeneca has a
powerful incentive to produce findings of Crestor's safety-and one way to
do that is through race-specific subgroup trials. Beyond ARIES, AstraZeneca
is also sponsoring two other race- and ethnic-specific Crestor trials: the IRIS
trial (Investigation of Rosuvastatin In South-Asian Subjects) and the
STARSHIP trial (STudy Assessing RosuvaStatin in the HIspanic
Population) .183
Similar dynamics are at work in Europe. In June 2005, over the
strenuous objections of the European Council of Human Genetics
("ESGH"), the European Patent Office granted a request by Myriad Genetics
to modify its patent relating to general testing for the BRCA2 genetic
mutation (which increases a person's risk of breast cancer) to apply
specifically to "diagnosing a predisposition to breast cancer in Ashkenazi
Jewish women."18 4 Opponents of the patent noted that the test currently is
available from other sources for all women regardless of ethnic or religious
background."' As a practical matter, this new patent means that individuals
identified as Ashkenazi Jews will either have to pay a premium for the test or
deny their identity." 6 As with BiDil, here Myriad apparently is marking an
ethnic group as genetically distinct not for scientific reasons but in order to
extend patent protection. Recent historical experiences of eugenics and
racial discrimination should give us pause when considering the potentially
profound consequences of the geneticization of such socially marked
188
groups.
A recent report from the Royal Society in the United Kingdom asserted
that realizing the promise of truly individualized pharmacogenomic
180. Press Release, AstraZeneca, AstraZeneca Presents New Data for CRESTOR in African-
American Patients with High Cholesterol at American Heart Association Annual Meeting (Nov.
8, 2004), available at http://www.astrazeneca-us.com/modules/PRMS/display.asp?id=38930.
181. Id.
182. Amanda Gardner, Gender, Ethnic Gaps Found in Heart Care, HEALTHDAY NEWS, Nov. 10,
2004, available at http://news.healingwell.com/index.php?p=newsl&id=522275.
183. Press Release, AstraZeneca, supra note 180.
184. Grit Kienzlen, BRCA2 Patent Upheld, SCIENTIST, July 1, 2005, available at
http://www.the-scientist.com/news/20050701/01.
185. M. Gessen,Jewish Guinea Pigs, SLATE,July 26, 2005, http://slate.msn.com/id/2123397.
186. Id.
187. Id.
188. See, e.g., DUSTER, supra note 136, passim; DANIEL KEVLES, IN THE NAME OF EUGENICS
passim (1998).
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therapies remains decades away." 9 In the gap between present reality and
future promises, there may be various strategies for capitalizing on emerging
genetic knowledge relating to drug response and efficacy. Targeting a racial
audience presents a particularly attractive interim option because, at this
point, the technology and resources do not exist to scan efficiently every
individual's genetic profile. Instead, businesses may market the product to a
particular social group that is hypothesized to have a higher prevalence of a
relevant genetic variation. Patent protection provides an essential
underpinning for such commercial ventures. As race is becoming more
relevant to marketing drugs, it is becoming a salient component of
underlying biotechnology patents.
Patent law provides a focused and dynamic site in which to identify and
examine emerging examples of race and genetics being mobilized in
tandem to serve both biomedical and commercial projects. As researchers
derive new inventions based on mining existing genetic databases, patent
law provides powerful commercial incentives to conflate race and genetics.
In approving such uses, the U.S. Patent Office gives the imprimatur of the
federal government to the reification of race as a genetic category. It also
puts the weight of federal authority behind such uses by placing the burden
of disputing such reification upon those (if any) who have the time, money,
expertise, and inclination to challenge the patents.
VI. THE RISE OF RACIAL PATENTS
A. PA TENr LA WBASJCS
A modern patent is a:
[G]overnment issued grant which confers upon the patent owner,
from the time the patent issues, the right to exclude others from
"making, using, offering for sale, or selling the invention
throughout the United States or importing the invention into the
United States" for a period of 20 years ending from the filing date
of the patent application.'90
This authority derives from the U.S. Constitution, Article 1, section 8, which
states: "The Congress shall have Power To . . . promote the Progress of
Science and useful Arts, by securing for limited times to authors and
Inventors the exclusive Right to their respective Writings and Discoveries."
All patent applications must meet several statutory requirements. The most
189. ROYAL SOc'Y, PERSONALIZED MEDICINES: HOPES AND REALITIES 1-3 (2005), available at
www.royalsoc.ac.uk/displaypagedoc.asp?id=158 74.
190. D. CHISUM ET AL., PRINCIPLES OF PATENT LAW 2 (Foundation Press 2001) (citing 35
U.S.C. § 154 (1994)).
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prominent of these are known as "useful [ness]" (or utility),' 9' "novelty,, 92
,, - v 1 ,193 0 , .- ,94
non-obvious[ness], and "specification.
The "usefulness" or "utility" requirement can be met by a showing that
the claimed invention has a specific, substantial, and credible utility.'95
"Specificity" requires the use to be specific to the character of the claimed
subject matter.19 6 A use is "substantial" if it involves a real-world use that
represents an end in itself. 97 A "credible" utility is one that would be
believable by a person skilled in the field of the invention. 9 8 The "novelty"
requirement is met if a single reference of "prior art," (e.g., another patent
or a published scholarly paper) does not "anticipate" (describe in its
relevant particulars) the invention.' 99 An invention meets the "non-
obviousness" requirement if "the differences between the subject matter
sought to be patented and the prior art are such that the subject matter as a
whole" would not be perceived as obvious to a person having ordinary skill
in the art (known in patent lingo as a "PHOSITA"). 200 "Specification"
requires a written description of the invention that is adequate to enable a
201PHOSITA to make and use the invention.
B. CONSTRUCTING THE NA TURE/CULTURE DIVDE IN PA TENT LAW
In the arena of biotechnology, patent law is premised on legally
202constructing a divide between nature and culture. In affirming the
patentability of a genetically engineered bacterium, the U.S. Supreme Court
asserted that patentable subject matter included "anything under the sun
made by man. " 203 DNA is made up on intermixed coding and non-coding
nucleotide sequences-exons and introns. The U.S. patent system
recognizes that genes can be patented to the extent that such patents are
based on information derived from complementary DNA ("cDNA")
sequences. In nature cDNA does not exist but is produced only through
human technological interventions that produce strands of DNA made up
191. 35 U.S.C. § 101 (2000).
192. Id. § 102.
193. Id. § 103.
194. Id.§ 112.
195. George Elliot, A Brief Guide to Understanding Patentability and the Meaning of Patents, 77
AcAD. MED. 1309, 1310 (2002).
196. Id. An oft used negative example here would be the failure to meet the requirement
by specifying the utility of a genetically engineered mouse to be "snake food."
197. 35 U.S.C. § 103(a).
198. Elliot, supra note 195, at 1309-14.
199. Id. at 1310-11.
200. 35 U.S.C. § 103(a).
201. Elliot, supra note 195, at 1312.
202. Kahn, What's the Use, supra note 15, at 419.
203. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
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only of exons with the intermixed introns deleted. °4 This intervention is
legally understood as isolating and purifying the DNA in manner that
effectively takes it out of the realm of nature and into the realm of society as
201an artifact of human creation.
DNA is not patented simply to claim title to a nucleotide sequence. It is
patented ultimately in order to bring some DNA-related product to market.
When that product is a drug, federal guidelines mandate that clinical-trial
data be collected with reference to social categories of race and ethnicity
promulgated by the OMB.2 °6 Ironically, and ominously, when race is used in
a gene-related °7 patent, a reverse of this transformation may occur. In such
patents, race begins as a social category, often derived from categories
specified by OMB directives.20 Biomedical professionals may link race to
genetic categories with the goal of somehow facilitating their research or
practice. But when the U.S. Patent Office issues a gene-related, race-
identified patent, the patent legally marks race as, at least in part, a genetic
category-i.e., the patent takes the social category of race and transforms it
into a "natural" category grounded in genetics.
Patent law is supposed to promote the invention of new and useful
products.200 In recent biotechnology patents, race and ethnicity are being
exploited in new ways that do not spur the invention of new products, but
rather the reinvention or recharacterization of existing products as racial or
ethnic.21° In so doing, patent law racializes intellectual property,
transforming it into a terrain for the re-naturalization of race as some sort of
204. The following is a brief elaboration of this process: Deoxyribonucleic acid ("DNA") is
composed of ordered combinations of four nucleotides: adenine, guanine, thymine, and
cytosine-generally abbreviated as A, G, T, and C. A given section of nucleotides along the
double-helical strands of DNA may code for certain amino acids that, in turn, provide a
particular protein. Protein synthesis occurs through a process where the genetic information
describing the protein is transcribed from the coding portion of the DNA molecule to a smaller
"messenger" molecule of ribose nucleic acid ("RNA"). This messenger RNA ("mRNA") then
combines with a ribosome and a third factor called transfer RNA ("tRNA") to produce a
protein. When scientists intervene in this process by adding the enzyme reverse transcriptase to
the mRNA, they produce a new and discrete DNA "transcript" that codes for the particular
protein. This transcript is known as cloned or complementary DNA ("cDNA"). PHILLIPE
DUCOR, PATENTING THE RECOMBINANT PRODUCTS OF BIOTECHNOLOGY AND OTHER MOLECULES
36-69 (1998); Michael Davis, The Patenting of Products of Nature, 21 RUTGERS COMPUTER & TECH.
L.J. 293, 310-15 (1995).
205. Kahn, What's the Use?, supra note 15, at 419, 426.
206. Food and Drug Modernization Act of 1997, Pub. L. No. 105-115, 111 Stat. 2296,
available at www.fda.gov/cder/guidance/105-115.htm (last visited June 14, 2002); FDA,
POPULATION PHARMACOKINETICS, supra note 71, at 5-6; U.S. DEP'T OF HEALTH & HUMAN SERVS.,
FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: COLLECTION OF RACE AND ETHNICry DATA IN
CLINICAL TRIALS 3-5 (2005), http://www.fda.gov/cder/guidance/5656fnl.htm.
207. See supra discussion accompanying notes 204-05.
208. See infra text accompanying notes 214, 218-26.
209. See D. CHISUM ET AL., supra note 190, at 1-2.
210. Kahn, Racial Categories, supra note 8, at 32.
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objective biological category. It also commodifies race as a good to be
patented and subjected to the dictates of market forces.
Federal patent and drug-approval processes provide an additional
incentive for using race and ethnicity to extend market protection for
existing drugs besides merely facilitating the approval of new drugs.
Concerns about the use of race are not merely hypothetical. Under the
Hatch-Waxman Act, an existing drug company can obtain up to three years
of market exclusivity (i.e., excluding competitors from the market) for FDA-
approved labeling changes based on information from new clinical
studies.'I Anecdotal evidence suggests that effective "[p]atent extensions
could be awarded for labeling changes that reflect new uses of drugs in
racial ... subpopulations" for approval of a new indication found for the
drug.
' 12
C. RACIAL PATENTS
A review of the "claims" and "abstract" sections of gene-related patents
and patent applications filed since 1976 indicates a significant trend toward
using race in gene-related patents with a marked increase in just the past few213
years. This rise coincides with both an increase in genetic information
being produced through the federally sponsored Human Genome and
HapMap Projects, and the rising federal emphases on requiring the use of
racial and ethnic categories in the collection of data relating to clinical trials
and drug applications.214
A typical patent is divided into several sections. The claims section
presents a primary focus for investigation because it is the legal heart of a
patent.215 The claims specify the legally operative scope of the patent,
defining the formal, legal "metes and bounds" of the territory covered by an• - 216
invention. The abstract is the basic summary presentation of the central
purpose of the patent. Other sections include the background or
217description of invention, plus drawings or other technical-support data.
The claims or abstract sections of patents that employ OMB Directive 15
categories of race and ethnicity in a manner implying or asserting a
genetic component to race 2 19 reveal the following:
211. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417,
98 Stat. 1585 (codified as amended in scattered sections of 21 U.S.C.).
212. Exclusivity Requests Based on Race, Age on the Horizon, 19 GENERIC LINE 24 (Dec. 2002)
(quoting Andrew Berdon) (on file with the Iowa Law Review).
213. See infra text accompanying notes 218-26.
214. See supra text accompanying notes 99-130.
215.. SCHECrER &THOMAS, supra note 3, at 404.
216. Id.
217. Id. at 423-24.
218. The results are from searches of the U.S. PTO patent database conducted between
Aug. 25, 2005 and Sept. 15, 2005, using the web-based search engine available at www.uspto.gov.
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Issued Patents Patent Applications
Category 1976-1997 1998-2005 Filed Since 2001220
Race 0 2 15
Ethnic 0 0 2
African-
American/Black
Alaska Native 0 0 0
Asian 0 0 13
Caucasian/White 0 6 18
Hispanic/Latino 0 0 3
Native American 0 0 2
Pacific Islander 0 0 1
Total 0 12 65
The results indicate a remarkable trend toward the increased use of
racial and ethnic categories in relation to patenting gene-related biomedical
innovations. Of the twelve uses identified in granted patents, the earliest
,221specifies the term "Caucasian." It relates to diagnostic testing for the
222
BRCA1 genetic mutation for breast cancer and was granted only in 1998.
The search terms used included: Race, Racial, Ethnic, Ethnicity, Caucasian, Caucasoid, African,
African-American, Negro, Negroid, Asian, Oriental, Mongoloid, Hispanic, Latino, Native
American, Alaska Native, Pacific Islander. The terms "Black" and "White" alone were too broad
to be useful and so were qualified with the additional terms of "gene" or "genetic" or
"nucleotide." Searches were also conducted using the terms "Jewish" and "Jew" because of the
distinctive history of the development of genetic screening technologies for diseases highly
prevalent in Ashkenazi Jewish populations. The terms yielded an additional seven patents in
each category. Yet because of this paper's focus on the OMB categories, these results will not be
incorporated into the present analysis.
219. This is an admittedly subjective basis for sorting the patents. The categorization of
patents that imply or assert a significant genetic component to race or ethnicity is meant to
exclude those patents that use racial/ethnic categories as one of many general demographic
characteristics, usually employed for organizing data rather than identifying or treating a
particular physiological state. The categorization is meant to include those patents that use
racial/ethnic categories as a basis for asserting a distinctive prevalence or etiology for a
physiological condition, genetic variation, and/or drug response.
220. Issued patents have been formally approved by the PTO. Patent applications are
currently pending for review before the PTO. Under new policies, applications are made
available to the public while pending review. U.S. Patent and Trademark Office, Frequently
Asked Questions About Patents, http://www.uspto.gov/web/offices/pac/doc/general/faq.htm
(last visited Sept. 18, 2006).
221. Coding Sequences of the Human BRCA1 Gene, U.S. Patent No. 5,750,400 (filed Feb.
12, 1997) (issued May 12, 1998), available at http://www.uspto.gov/patft/index.html (search
issued patents for "5,750,400").
222. Id.
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Two of the remaining patents, the first of which was granted in 2002, relate
to the drug BiDil, discussed above.223 The number of gene-related patent
applications using racial and ethnic categories from 2001-2005 is more than
five times the number of patents issued between 1976-2005. Although race
has previously been used in biomedical research, it has only recently taken
on increased significance in the commercial world of biotechnology
patenting. While there are some overlapping references (i.e., patents that
use more than one OMB category), the trend remains strong and tracks the
availability of vast new amounts of genetic information being produced and
classified in federally sponsored databases. For example, an application for
"Compositions and Methods for Inferring a Response to Statin"2 24 filed on
November 20, 2003, by Tony Frudakis, explicitly bases some of its race-
specific claims on samples taken from the Polymorphism Discovery
Resource, looking in particular for allele 225 frequencies in a "Caucasian"
population to infer a differential race-specific response to statin-a
226blockbuster class of cholesterol-lowering drugs.
D. THE USE OF RA CE IN BIOTECHNOLOGYPA TENTS
How exactly is race used in these patents? At the most pragmatic level,
patent applicants appear to be invoking race in a strategically defensive
manner to provide added protection against possible patent challenges. The
structure of a typical "claims" section of a patent begins with a preliminary
227claim that is as broad as possible. Successive claims increasingly narrow the
patent's focus. 22s Accordingly, if the broadest claim is struck down by the
patent examiner or on a subsequent challenge, the narrower claims may still
survive. Patent claims are thus structured something like a medieval castle,
with an outer ring encompassing the most territory, and successively smaller
rings providing additional layers of protection back to the core area of the
castle keep.
223. U.S. Patent No. 6,465,463 (filed Sept. 8, 2000) (issued Oct. 15, 2002), available at
http://www.uspto.gov/patft/index.html (search issued patents for "6,465,463").
224. Compositions and Methods for Inferring a Response to Statin, U.S. Patent Application
No. 20,030,215,819 (filed July 1, 2002), available at http://www.uspto.gov/patft/index.html
(search published applications for "20,030,215,819").
225. An "allele" is an "alternative form of a genetic locus; a single allele for each locus is
inherited from each parent (e.g., at a locus for eye color the allele might result in blue
or brown eyes)." Human Genome Program, U.S. Dep't of Energy, Dictionary of Genetic
Terms, http://www.ornl.gov/sci/techresources/HumanGenome/publicat/primer200l/
glossary.shtml (last visited Sept. 19, 2006).
226. U.S. Patent Application No. 20,030,215,819.
227. SCHECTER & THOMAS, supra note 3, at 409.
228. Id.
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A patent application for "[d]etection of susceptibility to autoimmune
diseases," 229 filed on July 1, 2004, exemplifies the use of concentric rings of
race to provide maximum protection for its claims. Its first three claims
provide the following:
1. A method for determining an individual's risk for type 1
diabetes comprising: detecting the presence of a type 1 diabetes-
associated class I HLA-C allele in a nucleic acid sample of the
individual, wherein the presence of said allele indicates the
individual's risk for type 1 diabetes.
2. The method of claim 1, wherein the individual is of Asian
descent.
3. The method of claim 1, wherein the individual is of Filipino
descent.
2 0
The application later repeats this structure for claims 22-24.31 Claim 1 is not
race-specific, referring only to an "individual's" risk. Claim 2 takes a smaller
subset of humanity, which it marks as "Asian."232 Claim 3 takes yet a smaller
subset of the group "Asian," which it marks as "Filipino." 231 In each case, the
applicant clearly links the categories to the HLA-C allele, specified in Claim
1, forcefully implying a genetic basis to the specific racial groups.
The logic of connecting race and genetics in this context, however, is
not driven by science so much as by the commercial imperatives of patent
law. The body of this patent application, which generally describes the
invention and its background, reviews the scientific literature underlying the
234claims. In this portion of the patent, which is of less legal significance, the
applicant invokes the terms "Asian" and "Filipino" to reference variable
235distributions of HLA allele frequency across populations. The description
section of the patent compares, in particular, the incidence of type 1
diabetes in populations in Japan and China to populations in the United
States and Europe.236 It goes on to discuss the frequency in the Philippines
as well. " ' In this context, the boundaries of the racial or national categories
are not hard and fast. It is not that "Asians" per se have different genes from
229. Detection of Susceptibility to Autoimmune Diseases, U.S. Patent Application No.
20,040,126,794 (filed Sept. 25, 2003), available at http://www.uspto.gov/patft/index.html
(search published applications for "20,040,126,794").
230. Id. (emphasis added).
231. Id.
232. Id.
233. Id,
234. U.S. Patent Application No. 20,040,126,794.
235. Id.
236. Id.
237. Id.
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"Europeans." Rather, it notes that there appear to be variable allele
frequency and disease incidence across certain populations. 38 Such uses of
population categories may generally remain problematic, but they are not
essentially genetically reductive because they deal with relative allele
frequencies that are acknowledged to exist across populations.
By contrast, in the "Summary of the Invention" section, the patent
states: "[t]he individual can belong to any race or population. In one
embodiment, the individual is an Asian, preferably a Filipino." 239 An
embodiment refers to the formal metes and bounds of the patent delineated
by the claims. Like the claims themselves, the Summary sets forth definitively
bounded categories that mark specified races as (genetically) distinct2
40
Here, the legal and commercial imperatives of effective patenting have
promoted the transmutation of variable genetic frequencies across
populations, that nonetheless all share common alleles, into bounded
genetic categories that are marked as distinct and functionally different.
Also of note in this patent application is that the category "Asian"
apparently is derived from studies only ofJapanese and Chinese subjects, 4'
thus conflating two national populations with an entire continent.
Moreover, there are separate claims regarding Asians and Filipinos, which
implies that Filipinos have some distinctive genetic basis that distinguishes
them from other populations encompassed by the larger category "Asian."242
This separate claim apparently is based on a study of ninety Filipinos
discussed in the body of the patent. 241
A similar pattern of concentric race-based patent claims is evident in an
application for "Cytotoxic T-Cell epitopes of HIV-1 virus" filed May 20,
2003.244 After beginning with a series of general claims relating to chemical
polypeptides used in vaccines and immunotherapies, the application makes
a series of claims related to the method of stimulating an HIV-specific
immune response. 245 As is common in many of the new race-specific patents,
it is in the methods claims that race becomes a salient category:
What is claimed is...
14. A method of stimulating an HIV-specific immune response,
comprising administering to a mammal an immunize comprising a
238. Id.
239. U.S. Patent Application No. 20,040,126,794.
240. Id.
241. Id.
242. Id.
243. Id.
244. Cytotoxic T-cell Epitopes of HIV-1 Virus, U.S. Patent Application No. 20,040,001,845
(filed May 20, 2003), available at http://www.uspto.gov/patft/index.html (search published
applications for "20,040,001,845").
245. Id.
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peptide epitope selected from the group consisting of SEQ ID NO:
3, 4, 6, 7, 8, 11, 12, 13, 14, 15, 18, 25, 26, and 27, wherein said
immune response comprises an increase in proliferation of H1V-
specific CD8+ T cells.
15. The method of claim 14, wherein said mammal is a human.
16. The method of claim 15, wherein said human is a member of a
Caucasian race.
17. The method of claim 15, wherein said human comprises an HLA
allele selected from the group consisting of A3, B7, and Cw7.
18. A method of stimulating an HIV-specific immune response,
comprising administering to a member of an asian race an
immunogen comprising a peptide epitope selected from the group
consisting of SEQ ID NO: 5, 6, 8, 10 and 11, wherein said immune
response comprises an increase in proliferation of HIV-specific
CD8+ T cells.246
Here, the defensive dynamic of concentric claims is clear, as the covered
categories move from mammal to human to Caucasian, each being used as
categories directly identified with gene sequences. "SEQ ID NO" is the
standard way of referring to a specified nucleotide sequence that is fully
elaborated in the body of a patent. In choosing to use race to build a
defensive patent claim, the applicants invoke broad terms, such as
"Caucasian" and "Asian," which clearly correspond with the OMB Directive
15 categories mandated by the NIH and FDA guidelines. Claim 18's
reference to "a member of the asian race" is also interesting because it
explicitly characterizes the racialized category "Asian" as a distinct genetic
pathway through association with a separate sub-set of nucleotide sequences.
And yet, several of the "SEQ ID NO" specified for the "Asian" race (6, 8, and
11) overlap with those specified in Claim 14, incorporated by reference to
apply to "Caucasians." The confusion of categories is, so to speak, patent-
and so is the geneticization of race.
E. THE UNSTATED WHITE NoRM IN BIOMwICINE
The use of the term "Caucasian" in this particular application is also of
interest because, unlike many of the other race-specific patents, it does not
assume an unmarked norm of "White." That is, many of the patents invoke
race when the inventors construct a perceived departure from an unstated
White norm (e.g., of disease or allele prevalence) in a non-White group. In
such contexts, the term "individual" or "human" implicitly stands for
"White" in the claims. As Rene Bowser notes:
246. Id. (emphases added).
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In nearly all racialized research published in the United States, the
comparison group has been the majority (White) population. Far
from being a neutral category, this approach consolidates Whites as
the group with which all "others" should be compared; it also
disregards research that demonstrates the value of studying
variations in health among, say, Blacks, as opposed to always
comparing them with White Americans. The norm in racialized
research is and has always been an unspoken but taken-for-granted
White norm.2 4 7
The use of a White norm is particularly evident in one of the BiDil patents.
Issued on October 15, 2002, the patent refers in Claim 1 to "[a] method of
reducing mortality associated with heart failure . . . in a black patient."2 48
Claim 2 goes on to specify "the method of Claim 1, wherein the black
patient has a less active renin-angiotensin system relative to a white
patient." 249 Here White is the norm from which Black deviates. As elaborated
in the "Background of the Invention," the patent goes on to assert that
"[h]eart failure in black patients has been associated with a poorer
prognosis than in white patients. In diseases such as hypertension, blacks
exhibit pathophysiologic differences and respond differently to some
therapies than whites."250 Beyond deviation from a White norm, the body of
the patent thus pathologizes Blackness as both biologically distinct and less
healthy.
Another typical example of the unstated White norm may be seen in a
patent application for a "[m]ethod of identifying a polymorphisms in
CYP2D6," filed June 5, 2002.25 The first Claim specifies "[a] method of
determining a cytochrome P-450 2D6 genotype of an individual .... 2152
Claim 12 specifies "[t]he method, as claimed in claim 1, wherein said
individual is Asian." 2 5 3 The focus on an "Asian" individual is explained in the
"Background to the Invention," which stipulates that "differences between
Caucasians and Asians are explained by an unequal distribution of CYP2D6
247. Rene Bowser, Racial Profiling in Health Care: An Institutional Analysis of Medical Treatment
Disparities, 7 MICH.J. RAcE & L. 79, 111 (2001) (citation omitted). For a recent discussion of the
role of an unstated White norm in the context of equal protection, see Juan Perea, Buscando
Ambrica: Why Integration and Equal Protection Fail to Protect Latinos, 117 HARV. L. REV. 1420, 1446-
53 (2004).
248. U.S. Patent No. 6,465,463 (filed Sept. 8, 2000) (issued Oct. 15, 2002), available at
http://www.uspto.gov/patft/index.html (search issued patents for "6,465,463").
249. Id.
250. Id.
251. Method of Identifying a Polymorphism in CYP2D6, U.S. Patent Application No.
20,030,170,651 (filed June 5, 2002), available at http://www.uspto.gov/patft/index.html (search
published applications for "20,030,170,651"). CYP2D6 is of particular interest to pharmaceutical
corporations because it is involved with drug metabolism.
252. Id.
253. Id.
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11• ,,254alleles. The application asserted different population-based allelic
frequencies between Caucasians and Asians; but this is a two-sided
difference-that is, each differs from the other. However, it is only Asians
that are specified in the claims as a sub-set of the broader term individual.
Caucasians logically could be put here, but are not similarly marked out. On
the one hand, this appears to be a failure of legal imagination to take
advantage of an additional defensive claim. On the other hand, it seems to
indicate an uncritical assumption that the categories "Caucasian" and
"individual" in the first claim were co-extensive and that only non-White
races counted as distinct sub-groups to be marked out as the basis for
defensive claims.
F. CONFLATING SAMPLES WITH RACES
On a related note, this patent, like many others, constructed a broad
racial category, "Asian," out of much smaller sub-groups. Further
examination of the "Background" section quoted above reveals that the
category "Asian" is actually based on a study of allele frequencies in what theS • ,,255
application terms "the Chinese population. Several paragraphs later it
turns out that the Asian-specific Claim is based on an analysis of "77 Asian
samples."25 6 This indicates that samples from seventy-seven individual
Chinese people came to stand for the entire population of China, which in
turn came to stand for "Asia." This sort of extended extrapolation from such
limited samples to huge racially marked populations is quite common both
in patents and the underlying studies upon which they are based.257 It
appears to be an artifact not only of the dynamics of patent law but also of
the tendency to conflate more specific population designators into the
broader racial categories defined by OMB Directive 15.
Perhaps most incongruous, yet illustrative of the strategic reification of
race and ethnicity in the context of biotechnology patents, are the few
patent applications, such as one for "manganese superoxide dismutase gene
polymorphism for predicting cancer susceptibility,"258 that invoke "Hispanic"
as a genetic term. This patent's first Claim specifies:
A method of determining relative age-related risk of colorectal
cancer in a Hispanic subject, comprising: determining whether a
first and/or second allele of a manganese superoxide dismutase
(MnSOD) gene in the subject comprise a mutation in the coding
254. Id.
255. Id.
256. U.S. Patent Application No. 20,030,170,651.
257. Kahn, Genes, Race, and Population, supra note 149, at 7-9.
258. Manganese Superoxide Dismutase Gene Polymorphism for Predicting Cancer
Susceptibility, U.S. Patent No. 6,716,581 (filed Apr. 2, 2001) (issued Apr. 6, 2004), available at
http://www.uspto.gov/patft/index.html (search issued patents for "6,716,581").
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region for the mitochondrial targeting sequence (MTS) of the
MnSOD protein resulting in a loss of .alpha.-helical structure in the
MTS. 259
The description of the invention mentions, at one point, a "Study
Population" of "Hispanics and Non-Hispanic White Americans," 260 but this is
the only reference to non-Hispanics in the application. As elaborated later
in the description section, the claims are based on a study of "[s]ixty four
(64) Hispanic patients with colorectal cancer and 63 Hispanic disease free
controls. 26' This appears to be an additional example of using race or
ethnicity as a default classification when applicants have only a single race or
ethnicity in their studies. This particular application, however, is distinctive
both for its foregrounding of ethnicity in its first Claim and for its genetic
reification of the ethnic category "Hispanic," which generally does not have
the same pronounced history of reification as racial categories such as
"African" or "Asian."262 Indeed, as an ethnic category, "Hispanic" is so diffuse
and diverse that it does not even have a purported link to continental
ancestry, which sometimes undergirds justifications for using racial
263categories as surrogates for ancestral-descent populations.
G. VALORIZING "WHITE" GENES
264
As the chart of race-specific patents indicates, there are many
references to "Caucasians." Several of these involve disease conditions and so
may be understood implicitly to pathologize Whiteness as well. Upon closer
examination, however, two qualifying characteristics mark Whiteness in
several of these patents as neither deviant nor pathological. First are
situations where the overwhelming majority of test subjects in the studies
underlying a patent were White, and so Whiteness becomes a sort of default
category for an additional defensive claim. Second are patents that invoke
Whiteness to mark the improved differential efficacy of a potential medical
treatment (in contrast to a differential burden of disease, as was the case
with BiDil).
In a patent application for "[g] enetic diagnosis of depression," the first
Claim specifies "[a] method of identifying individuals predisposed to major
259. Id. (emphasis added).
260. Id. at [138].
261. Id. at [140].
262. See Sharona Hoffman, "Racially-Tailored" Medicine Unraveled, 55 AM. U. L. REV. 395, 414-
16(2005).
263. See, e.g., Niel Risch et al., Categorization of Humans in Biomedical Research: Genes, Race and
Disease, 3 GENOME BIOLOGY comment 2007 (2002), available at www.genomebiology.com/
content/pdf/gb-2002-3-7-comment2007.pdf.; Noah A. Rosenberg et al., Clines, Clusters, and the
Effect of Study Design in the Inference of Human Population Structure, 1 PLOS GENETICS 660 (2005),
available at http://rosenberglab.bioinformatics.med.umich.edu/papers/clinesclusters.pdf.
264. See supra text accompanying notes 219-21.
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depressive disorder." 265 Its race-specific Claim 4 specifies: "[t] he method of
claim 1, wherein said subject is Caucasian.2 66 At first blush, the patent might
seem to be pathologizing Whiteness by associating it with depression. Upon
closer examination, however, it turns out that the studies underlying the
invention were conducted in an exclusively "Caucasian" population (which
the patent defines rather broadly as members of "the white race consisting
of individuals of European, north African, or southwest Asian ancestry") .267
The clinical studies alluded to in the body of the patent did not show
anything distinctive about Caucasians that would identify them as having
race-specific markers for depression that differentiated them from any other268
race. Following the logic of patent law, rather than science, the patent
employed race defensively, as race has come more commonly to be
understood and accepted as a legitimate and salient category both in genetic
research and in patent strategy.269 Having learned to see race as relevant to
patent protection, the inventors likely invoked the category "Caucasian"
270because it was the only available race they could extract from their data.
A patent for "[p] eptide-based vaccine for influenza" exemplifies the use
of Whiteness as a target for improved therapy.2 7' Its first claim refers to "the
NP380-393 epitope according to SEQ ID NO:5 that are the most prevalent
,,272HLA molecules in a Caucasian human population. As elaborated in the
description section, the patent specifies that the vaccine will change
"according to the population type" and asserts that "the CTL influenza
epitopes are different in the Caucasian, the Asia- or Africa-originated
population [sic].,,273 The patent does not define these populations, but it
refers to them elsewhere as "Caucasian and non-Caucasian," privileging
265. Genetic Diagnosis of Depression, U.S. Patent Application No. 20,040,132,062 (filed
July 8, 2004), available at http://www.uspto.gov/patft/index.html (search published
applications for "20,040,132,062").
266. Id.
267. Id. at [21], [146].
268. Id.
269. Id.
270. A similar dynamic may be observed in Treatment of Ocular Hypertension and
Glaucoma, U.S. Patent No. 6,458,836 (filed July 9, 2001) (issued Oct. 1, 2002), available at
http://www.uspto.gov/patft/index.html (search issued patents for "6,458,836"), which also
employed race defensively in the claims section where the invention was based on a study of
"813 human subjects, mostly Caucasian."
271. Peptide-Based Vaccine for Influenza, U.S. Patent No. 6,740,325 (filed July 30, 2001)
(issued May 25, 2004), available at http://www.uspto.gov/patft/index.html (search issued
patents for "6,740,325").
272. Id. (emphasis added). An epitope is a single antigenic site on a protein against which
an antibody reacts.
273. Id.
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Caucasian as the norm.274 Indeed, Caucasian is the only race specified in the
275legally enforceable claims section, making it a target of the invention.
Similarly, in a patent application for a "[m]ixture of peptides derived
from e6 and/or e7 papillomavirus proteins and uses thereof,"276 the first
Claim asserts, inter alia:
A mixture of peptides derived from an E6 protein and/or from an
E7 protein of an HPV [human papilloma virus] involved in cervical
cancer or benign lesions of the skin, characterized in that each of
the peptides included in said mixture binds to at least one HLA-
DRB1 (1st gene) molecule the frequency of which is greater than
5% in the Caucasian population .... 277
As elaborated in the description section, this invention relates to developing
uses for "a medicinal product" or "diagnosing T lymphocytes specific for an
HPV. 278 The patent explicitly sets forth the aim of providing an invention
that will be effective "in the majority of European and North American
Caucasian individuals." 279 Consequently, the patent characterizes the
invention of terms of a gene with a particular frequency in the Caucasian
280population. Unlike the BiDil patent, which characterizes Blacks as having
a worse prognosis than Whites, this application does not use Caucasian as a
term that deviates from a particular norm or has a pathological gene
variation, but rather as a population with a gene variation that will enable it
to take advantage of the proposed invention. Here Caucasian genes are
presented as positive and empowering, providing the basis for an effective
medical intervention.
One reason for the use of different terms is that Caucasian genes are
where the money is. This is made abundantly clear in a patent application
for "[m]ethods for obtaining and using haplotype data,"212 filed December
21, 2001, by scientists from Genaissance Pharmaceuticals, a biotech company
that describes itself as "a world leader in the discovery and use of human
274. Id.
275. Id.
276. Mixture of Peptides Derived from e6 and/or e7 Papillomavirus Proteins and Uses
Thereof, U.S. Patent Application No. 20,040,170,644 (filed Nov. 2, 2004), available at
http://www.uspto.gov/patft/index.html (search published applications for "20,040,170,644").
277. Id
278. Id. at [001].
279. Id. at [0042]. Ironically, it also acknowledges the "relative imprecision of this
approach." Id.
280. Id. at [0036].
281. U.S. Patent Application No. 20,040,170,644.
282. Methods for Obtaining and Using Haplotype Data, U.S. Patent Application No.
20,040,267,458 (filed Dec. 21, 2001), available at http://www.uspto.gov/patft/index.html
(search published applications for "20,040,267,458").
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gene variation for the development of personalized medicine."283 The
market model of Genaissance capitalizes on human genetic variation and
holds a stake in finding population-specific genetic differences. In
developing new products, Genaissance mines existing federally maintained
284genetic databases as an exploitable resource. This resource already
employs a myriad of population categories that are ripe for conflation with
the OMB Directive 15 social categories of race.
Genaissance's patent application for "[m]ethods for obtaining and
using haplotype" explicitly capitalizes on the type of data being produced by
the HapMap project. This application begins with a broad Claim to "[a]
,,28,5method of generating a haplotype database for a population. It goes on
in Claim 8 to specify that the reference population may include an "ethnic
,,216population, thereby directly connecting ethnicity to genetics. In
describing the "Field of the Invention" after the claims section, the patent
marks pharmacogenomic uses as primary, noting that genetic haplotype
information can be used "to predict an individual's susceptibility to a
particular disease and/or their [sic] response to a particular drug. 211 It also
notes that "the invention may also be used to link variations in DNA to
personal identity and racial or ethnic background. " 288 Here the patent
applicant invokes the pharmacogenomic promised land of personalized
medicine, but the invention largely depends on using racial and ethnic
categories as proxies for genetic variation. This is precisely because the
practical reality of the widespread use of individualized therapy remains far
in the future.
To this point, the Genaissance patent uses race and ethnicity broadly,
without singling out any particular group. Strikingly, however, in the
"Detailed Description of the Invention," the patent elaborates on one
particular embodiment of the invention, declaring:
283. Exhibit 99.1, Genaissance Pharmaceuticals Reports First Quarter Results, May
13, 2003, available at http://sec.edgar-online.com/2003/05/13/0001104659-03-009273/
Section5.asp.
284. Association of Beta2-Adrenergic Receptor Haplotypes with Drug Response,
Genaissance's Patent Application No. 20,030,091,998, filed on May 15, 2003, provides another
telling example. It includes a claim for "[a] method for predicting a Caucasian individual's
genotype for one or both of PS9 and PS1O in the individual's .beta..sub.2AR gene ...." The
invention goes on to describe genetic samples taken from individuals identified as "Caucasian,"
"African descent," "Asian" and "Hispanic-Latino." The samples, it turns out, come from the
publicly maintained GenBank database. Some of the "Caucasian" samples in particular are from
the "CEPH-Utah cohort" that is maintained as part of the NIGMS-Coriell Human Genetic
Variation database. Association of Beta2-Adrenergic Receptor Haplotypes with Drug Response,
U.S. Patent Application No. 20,030,091,998 (filed May 15, 2003), available at
http://www.uspto.gov/patft/index.html (search published applications for "20,030,091,998").
285. U.S. Patent Application No. 20,040,267,458.
286. Id.
287. Id.
288. Id.
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Analysis of the candidate gene(s) (or other loci) requires an
approximate knowledge of what haplotypes exist for the candidate
gene(s) (or other loci) and of their frequencies in the general
population. To do this, a reference population is recruited, or cells from
individuals of known ethnic origin are obtained from a public or
private source. The population preferably covers the major
ethnogeographic groups in the U.S., European, and Far Eastern
pharmaceutical markets.
2 89
This description weaves genetic categories based on haplotypes together
with social categories of ethnicity ("ethnic origin") into the concept of a
"reference population. " 290 This is essential to a marketing strategy that
exploits race in the gap between current realities and the promised future
benefits of individualized pharmacogenomic therapies. That is, current
technology does not allow Genaissance effectively or economically to market
to people with specific genotypes. It can, however, capitalize on well-
established techniques of "ethnic niche marketing" for a wide variety of
291products to target specific racial groups. Second, the description, whether
intentionally or not, is a brazen declaration that ethnicity only matters where
markets matter-the United States, Europe, and the Far East. The rest of the
world, including Africa, South America, the Middle East, and South Asia,
apparently is irrelevant. The patent invokes ethnicity not solely as a short cut
to finding genetic correlations with particular population groups, but also,
and inextricably, as a basis for developing drugs for major markets. In this
context, the reference to ethnogeographic groups serves as a quasi-genetic
category conflating ethnicity with geography as a basis for identifying
lucrative markets. Ethnicity here becomes a function not only of genes, but
also of genes plus markets.
VII. THE EMERGING POLITICAL GEOGRAPHY OF
RACIALIZED INTELLECTUAL PROPERTY
In cases such as BiDil and the Myriad Genomics BRCA2 test, racialized
patents appear to play a central role in the marketing strategy for the
product. Both cases involve technologies that were already in use. Adding
race to the patents did not change the technology so much as it provided an
added incentive to market and to extend monopoly control for the product.
This moves beyond the defensive use of race in claims and extends to an
affirmative projection of race as a central component of product
289. Id. (emphasis added).
290. U.S. Patent Application No. 20,040,267,458.
291. See, e.g., TamarJacoby, Adjust Your Sets: Meet the Power Behind Segregated Television- You.,
THE NEW REPUBLIC, Jan. 24, 2000, available at http://www.manhattan-institute.org/html/mtnr-
adjust.htm; MarketResearch.com, supra note 6; Multicultural Edge, Inc., Niche Marketing
Services and Programs, http://www.multiculturaledge.com/products.hun (last visited Sept. 19,
2006).
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development and marketing. In the case of BiDil, race unmistakably added
publicity value to the product." ' A good deal of the publicity was produced
by social understandings that reified race as genetic. 2 3 Thus, for example, in
addition to casual references to a race-specific genetic basis for BiDil's
efficacy in the popular media, articles published in such scientific and
professional journals as Genome Biology,2 94 the British Medical Journal,2 5 and
Health Affairs 9 6 have also incorrectly asserted a genetic variation more
prevalent in self-identified African Americans to underlie BiDil's efficacy.
To more fully appreciate the dynamics of, and reification of race in,
racialized patents, it is useful to explore (1) how race-ing patents changes
the concepts and dynamics of claims that can be made for, about, or on
behalf of race; and (2) how patenting race changes the terrain of patent law.
A. RACE-ING PATENTS: WHATDoES RACE ADD?
To assess what race adds, we begin with a consideration of how
racializing biotechnology patents also racializes the basic criteria of patent
validity: utility, novelty, non-obviousness, and specification.
1. Utility
The requirement of utility is generally regarded as fairly de minimus,
demanding only that the invention achieve some sort of pragmatic result.
2
1
7
Often, the concept of utility is conflated with marketability-if someone is
"willing to pay for [it], it must be useful."298 Nonetheless, it is apparent that
invoking race is deemed "useful" by patent applicants, in both the colloquial
and formal legal sense of the term. Race is most commonly useful as a
defensive claim, adding another ring to the battlements of patent
protection. But race can only stand if it is deemed relevant to the invention.
It should be contributing some utility to the invention-making it somehow
different than it otherwise would be absent race. In many instances, race is
not being used as an end in itself, but as a proxy or surrogate for identifying
populations that are deemed relevant targets for a particular invention. In
this regard, patent applicants may be using race as the equivalent of a
"research tool."299
292. Kahn, Racial Categories, supra note 8, at 31.
293. Kahn, Letter to the Editor, supra note 158, at 655.
294. Gregory A. Petsko, Comment, Color Blind, 5 GENOME BIOLOGY 119, 119 (2004).
295. Taslin Rahemtulla & Raj Bhopal, Pharmacogenetics and Ethnically Targeted Therapies, 330
BRITISH MED.J. 1036, 1036-37 (2005).
296. RickJ. Carlson, The Case of BiDil: A Policy Commentary on Race and Genetics, HEALTH AFF.,
Oct. 11, 2005, http://content.healthaffairs.org/cgi/content/abstract/hlthaff.w5.464vl.
297. SCHECTER &THOMAS, supra note 3, at 315-21.
298. Kahn, What's the Use?, supra note 15, at 435.
299. Arti K. Rai, Genome Patents: A Case Study in Patenting Research Tools, 77 ACAD. MED. 1368,
1368 (2002) [hereinafter Rai, Genome].
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A research tool is, as the name suggests, an invention that may not have
a broad commercial market but is of interest to researchers in conducting
further investigations that ultimately may lead to a marketable product.31° In
gene patenting, an expressed sequence tag ("EST") is often characterized as
a research tool. °  An EST is a relatively short sequence of DNA that can be
302used to help identify complete genes. Such diagnostic probes often have
no utility outside the lab. Inside the lab, they have uses and a market, insofar
as other researchers can be considered a market. In broader debates about
the propriety of patenting human genes, some scientists express concern
303that the proliferation of gene patents may be inhibiting scientific progress
and argue that gene-based research tools used only by other scientists should
304not be patentable °. Others make a further distinction, questioning in
particular the wisdom of patenting research tools that function as "research
platforms"-technologies that underlie a broad range of basic research
(such as the Cohen-Boyer patent on recombinant DNA technology).105 Such
technologies may not need patent protection to incentivize their
development because they are so basic to research that they will go to
306market regardless of the prospect of future remuneration.
As a research tool, an EST is used as a surrogate-it marks an area that
may correlate with a more useful, complete gene sequence, but does not
itself constitute an independent invention with a use outside the lab.307 In
many racialized patents, race is also used as a surrogate-for example, for a
group of people who are more likely to respond (or not) to a particular
drug or disease. Often, the patents use race as a surrogate for extended lines
of further surrogates-as where race is used to mark a population group,
which is used to mark a particular frequency of a specific allele, which, in
turn, is used to mark a higher (or lower) probability of disease susceptibility
308or drug response. In these patents, race is not more independently
300. Id.
301. Id.
302. MedicineNet.com provides the following definition: "EST (expressed sequence tag): A
unique stretch of DNA within a coding region of a gene that is useful for identifying full-length
genes and serves as a landmark for mapping." MedicineNet.com, http://www.medterms.com/
script/main/art.asp?articlekey=3328 (last visited Oct. 7, 2006).
303. Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The
Anticommons in Biomedical Research, 280 SCIENCE 698, 698-701 (1998).
304. Kahn, What's the Use?, supra note 15, at 436-37; Kate Murashige, Patents and Research-
An Uneasy Alliance, 77 ACAD. MED. 1329, 1329-38 (2002).
305. Rai, Genome, supra note 299, at 1369; see also Arti K. Rai & Rebecca S. Eisenberg, Bayh-
Dole Reform and the Progress of Biomedicine, 66 LAW & CONTEMP. PROBS. 289, 300 (2003)
(explaining that the Cohen-Bayer method did not require exclusive rights in order to "achieve
widespread dissemination and use").
306. Jorge A. Goldstein & Elena Golod, Human Gene Patents, 77 ACAD. MED. 1315, 1324
(2002). See generally Rai, Genome, supra note 299.
307. SeeGoldstein & Golod, supra note 306, at 1318-19.
308. Kahn, Genes, Race, and Population, supra note 149.
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operative or productive of a useful invention than is an EST. Both are used
as a sort of probe to uncover or make manifest other uses. A racialized
biotechnology patent typically links race to presumed group-based genetic
differences underlying different responses to drugs or disease susceptibility.
While the patent constructs race as useful, it also invariably constructs it as
genetic. Race, however, does not function like a research platform insofar as,
absent the patent advantages it conveys, there is often little reason to
otherwise use race in a claim. In a curious tautology, race becomes useful
precisely because it is patentable. Race is patentable because it is reified as
genetic; and it is reified as genetic in order to render it patentable. The
primary utility of race, however, is legal and commercial, providing extra
layers of patent protection. The tenuousness of race's scientific or medical
utility is evident in the more extensive discussions of racial categories in the
less-legally-potent description sections of patents, where racial categories are
often acknowledged to be only rough surrogates for differing allele
frequencies that exist across all populations. 3 9 To meet the requirement of
utility, race must be constructed, at least implicitly, as fixed and stable-as
genetic. But, if more appropriately understood as, at best, a tenuous
surrogate category that is ultimately grounded in complex and mutable
social understandings, race would not add clear utility to these patents.
2. Novelty
To meet the requirement of novelty, an invention must not be
"anticipated" in a single prior art disclosure that contains every element of
the claimed invention.3 1 ° Almost any biotechnology invention can be made
novel through the simple addition of race. This is apparently what happened
in the case of BiDil. Jay Cohn, the holder of the BiDil patents, first filed in
1987 for a non-race-specific patent to use the generic components of BiDil
to treat heart failure in the general population.311 This patent expires in
2007.312 After the FDA turned down the first new drug application for BiDil
in 1997 (on the grounds that the statistics submitted in support of the
application were too muddled to make a finding as to whether BiDil
worked), Cohn filed a reformulated race-specific patent in 2000.314 This
315patent does not expire until 2020. It provided the basis for licensing the
rights to BiDil to NitroMed.316 In turn, the race-specific patent enabled
309. See supra discussion accompanying notes 229-63.
310. SCHECTER & THOMAS, supra note 3, at 363-64.
311. Kahn, Racial Categories, supra note 8, at 13.
312. Id. at 32.
313. Id. at 15.
314. U.S. Patent No. 6,465,463 (filed Sept. 8, 2000) (issued Oct. 15, 2002), available at
http://www.uspto.gov/patft/index.html (search issued patents for "6,465,463").
315. Kahn, Racial Categories, supra note 8, at 32.
316. Id. at 31-32.
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NitroMed to raise over $30 million in venture capital to fund the A-HeFT
trials, 7 which provided the basis for the FDA's ultimate approval of BiDil as
a race-specific drug in June 2005.31 s For Jay Cohn and NitroMed, the
patentable novelty of race added time and money to their invention-to wit,
an extra thirteen years of monopoly market control over the use of BiDil
and essential venture capital needed to get A-HeFT off the ground.
In a case such as BiDil, one might well ask how the addition of race,
specifically being Black, can mark the method of administering the drug as
new when the previous patent for essentially the same method covered all of
humanity. The answer seems to be that the previous non-race-specific patent
was premised on an unstated White norm that excluded non-Whites.1 9 The
perception is that identified and articulated Blackness is novel because it is
not White. More troubling still is the further implication that Blackness is
somehow not encompassed by a general non-race-specific patent that
presumably covers all human beings. Indeed, this was the tacit message sent
by the FDA's approval of BiDil for use only by African Americans. The
rationale for such approval was that the A-HeFT trials tested the drug only in
self-identified African American subjects.32 ° But most drugs on the market
today were approved by the FDA based on trials conducted almost
exclusively in White populations.32 ' These drugs, however, are not
designated as "White" drugs. The operating assumption for such general
approvals was that, for the purposes of drug approval, the category "White"
differed in no meaningful way from the category "human being." In
granting race-specific approval for BiDil based simply on the fact that the
trial population was all "'self-identified' African Americans," the FDA sent
the message that the category "African American" is somehow less than fully
coterminous with the category "human being."3 22 This marks the logical
extension of the rationale for the underlying patent that drove the design of
A-HeFT, which presumes that adding race marked the invention as
somehow new and different. Without the implicit logic supplied by the
unstated White norm, the BiDil patent, and others like it, would fail to meet
the requirement of novelty.
3. Non-obviousness
As mentioned above,323 the non-obviousness requirement is met if "the
differences between the subject matter sought to be patented and the prior
art are such that the subject matter as a whole" would not be perceived as
317. Id. at 24.
318. Kahn, False Promises, supra note 166, at 6.
319. See Bowser, supra note 247, at 111.
320. Kahn, False Promises, supra note 166, at 6.
321. Id.
322. Id.; see also Sankar & Kahn, supra note 65, at W5-461-62.
323. See supra Part VIA.
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obvious to a "person having ordinary skill in the art."32 4 Explicitly marked
race similarly becomes non-obvious when the unstated norm is White-it
being non-obvious that unmarked population groups would contain non-
Whites; or rather, it being assumed in retrospect that the unstated White
norm did not contain non-Whites. Ironically, this dynamic works in the
context of biotechnology patents in part because of the hard work done by
social scientists to mark race as a social category. 2 5 It is precisely because
patent applicants and PTO examiners are willing to accept the "obviousness"
of race as a social construct that race as genetic can be construed as "non-
obvious," and hence a relevant, patentable use of race in biotechnology
inventions. Social race alone is deemed too obvious to be of use to the
patent applicant. The description sections of biotechnology patents thus
commonly treat race as a social category that acts as a surrogate for genetic
variations in particular populations. In contrast, the salient claims sections
make more definitive associations between race and genes and are
presented as so scientifically sophisticated and distinctive as to be useful,
novel, and non-obvious. To mark out definitive metes and bounds of a
biotechnology patent, surrogate markers and correlations become
naturalized into fixed racial categories, thereby producing a previously
unarticulated, purportedly genetic component to race. Yet, as discussed
above, race is not a coherent genetic category.:16 Therefore, such uses of
race should be insufficient to meet the requirement of non-obviousness.
The patents' implicit construction of social race as obvious is further
evidenced by their general failure to provide any substantive definition of
the terms "race" or "ethnicity" or to define any of the specific racial
categories they use. This stands in marked contrast to the care that is taken
in defining certain scientific terms regarding specific chemical compounds
or genetic terms employed in the body of the patent. Some notable
exceptions exist that, perhaps, underscore the general presumption that
race is an intuitively obvious social category and, therefore, does not need to
be given careful or extensive consideration.
Prominent among these are the two patent applications that provide
perhaps the most concrete and specific definitions of the racial category
they employ. In both cases the category is "Caucasian." The first, "[m]ethod
of determining susceptibility to inflammatory bowel disease,"3 27 filed
November 4, 2004, defines Caucasian as "a native of Europe, North Africa,
324. 35 U.S.C. § 103(a) (2000).
325. See, e.g., AAA, Statement, supra note 43; AM. SOCIOLOGICAL Assoc. (ASA), THE
IMPORTANCE OF COLLECTING DATA AND DOING SOCIAL SCIENTIFIC RESEARCH ON RACE (2003),
available at http://asanet.org/galleries/default-file/asa racestatement.pdf.
326. See supra notes 32-47 and accompanying text.
327. Method of Determining Susceptibility to Inflammatory Bowel Disease, U.S. Patent
Application No. 20,040,219,555 (filed Nov. 4, 2004), available at http://www.uspto.gov/patft/
index.html (search published applications for "20,040,219,555").
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Western and Central Asia, Australasia, and America. Preferably the term
Caucasian excludes Japanese subjects."128 The breadth of the definition is
staggering, encompassing perhaps a majority of the world's population
(especially if one assumes that Japanese and other East Asians, while
"preferably" excluded, could be included). The definition appears to be
geographically based, providing the impression that the category is linked to
some concept of biological descent. But it is also glaringly imprecise. On the
one hand, the term "native" would presumably be understood as someone
born in that locale. If so, certainly people with recent descent from sub-
Saharan Africa would qualify as "natives" of any one of these areas. If, on the
other hand, "native" is presumed to include some notion of a longer lineal
descent from populations local to the specific geographic area, then Native
Americans would qualify as Caucasian by this definition.
,,329The second application, "[g]enetic diagnosis of depression, uses a
similar but slightly more focused definition of "Caucasian." It refers "to a
member of the white race consisting of individuals of European, north
African, or southwest Asian ancestry."3 0 While geographically more limited,
the most important qualifying term in the definition is "white race." This
addresses some of the overbreadth issues presented by the previous
definition but presents a basic problem of tautology. The application, in
essence, defines Caucasian as a member of the "white race." Yet, as Ian
Haney L6pez makes abundantly clear in his powerful analysis of the legal
construction of race, the relation between White and Caucasian historically
has been anything but obvious. In his book White by Law, 32 Haney L6pez
discusses the case of United States v. Thind,333 in which a man from India
argued for his own naturalization under U.S. law, claiming to be a
Caucasian. Haney L6pez notes that after reviewing anthropological theories
of the races, the Court concluded that although Thind may technically
qualify as a Caucasian in terms of social science, he was not "White" as
commonly understood in general social terms, which were presumed to have
informed relevant policy and legislation. 34 As Haney L6pez makes crystal
clear, the categories "White" and "Caucasian" are not necessarily co-
extensive.33 5
328. Id.
329. Genetic Diagnosis of Depression, U.S. Patent Application No. 20,040,132,062 (filed
July 8, 2004), available at http://www.uspto.gov/patft/index.html (search published
applications for "20,040,132,062").
330. Id.
331. IAN F. HANEY LOPEZ, WHITE BY LAW: THE LEGAL CONSTRUCTION OF RACE passim (New
York University Press 1996).
332. Id.
333. United States v. Thind, 261 U.S. 204 (1923).
334. LOPEZ, supra note 331, at 90-94.
335. Id. at 86-94.
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Perhaps, then, the application for "[g]enetic diagnosis of depression"
was using the term "white race" to limit the broader term "Caucasian."
Indeed, when read in relation to the first application's nearly all-
encompassing use of the term, such a construction seems reasonable. The
second application, however, does not go on to define the term "white
race"-precisely because it is understood as an intuitively obvious social
category. In the end, like the Court in Thind, this application assumes the
category "white" to be social rather than scientific, hence obvious and in
need of no further definition or clarification.
Significantly, the BiDil patent defines the term "black" as "a person of
African descent or an African-American person."336 This definition also
mixes geographical concepts of localized descent with the social category of
African American, which could involve multiple lines of descent to various
populations around the world. Unlike the definitions of Caucasian above, it
does not distinguish between any regions within Africa. Moreover, the data
on which the patent is based and the follow-up study that provided the basis
for FDA approval, were based on subjects who "self-identified" as Black.
3
1
Self-identification is a social, not a genetic process. There is a logic to the
BiDil patent being one of the few to attempt a modest definition of race
grounded in social concepts-it is also the basis for the first race-specific
drug approval that is being marketed to African Americans as a social
338group-not as a genetic group.
These patents' treatment of race as a purportedly obvious social
category in contrast to a presumedly non-obvious genetic category is
particularly evident in a patent application for "[c] ompositions and methods
for inferring ancestry, 3 9 filed November 18, 2004, by Tony Frudakis of
DNAPrint Genomics. DNAPrint describes itself as "a cutting edge company.
We are concentrating our efforts in four distinct areas: Pharmacogenomics,
Forensics, Genotyping, and Consumer Products. Our aim is to continue to
research and develop novel products and services in each of these market
areas and to be a leader in genomic-based technologies." 40 Frudakis is
claiming a method of using ancestry-informative DNA markers for inferring
the ancestry of a given individual. Claim 3 specifies the ability to infer what it
calls "[b]iogeographical ancestry."3 4' Later, in the description section, the
336. U.S. Patent No. 6,465,463 (filed Sept. 8, 2000) (issued Oct. 15, 2002), available at
http://www.uspto.gov/patft/index.honl (search issued patents for "6,465,463").
337. Taylor et al., supra note 64, at 2050.
338. Kahn, Racial Categories, supra note 8, at 24-28.
339. Compositions and Methods for Inferring Ancestry, U.S. Patent Application No.
20,040,229,231 (filed Nov. 18, 2004), available at http://www.uspto.gov/patft/index.html
(search published applications for "20,040,229,231").
340. DNAPrint Genomics, Corporate Profile, available at http://www.dnaprint.com/
welcome/corporate/ (last visited Sept. 19, 2006).
341. U.S. Patent Application No. 20,040,229,231.
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application defines "Biogeographical ancestry" as "the heritable component
of 'race.' 342 What is striking about this particular use of race in relation to
genetics is the way in which Frudakis distinguishes between social and
purportedly genetic aspects of race. It is genetic race-the heritable
portion-that Frudakis claims is revealed through analysis of ancestry-
informative markers that he marks out as a distinctive basis for the patent.
And yet, while acknowledging that non-heritable race components do exist
(and, indeed, necessarily must be relevant to the actual application and
commercial utility of the technology), the patent makes no attempt to
define them. Again, the implicit assumption appears to be that the asserted
genetic components of race are non-obvious and/or novel, while the social
aspects of race are too obvious to warrant further consideration.
4. Specification
The concept of "enablement" is at the heart of the requirement of
specification. The written description of the invention must be sufficient to
enable a person skilled in the art to make and use the invention.34 3 Where
non-obviousness relies on a previously unseen genetic basis for race,
enablement relies on the presumed obviousness of race as a social category
to facilitate the later use of the invention by other PHOSITAs. Thus, for
example, a reference to "Asians" or "Blacks" or "Caucasians" may be deemed
enabling precisely because those categories are not seen as problematic.
Rather, they are implicitly cast as merely social and hence obvious. Social
scientific constructions of race as complex, difficult, and problematic
categories3 " cannot be allowed to enter this realm because they would
challenge the assumptions underlying the patent's racial enablement.
Schecter and Thomas note that in so-called "unpredictable arts," such
as biotechnology or some branches of chemistry, courts are often stricter in
reviewing whether a particular written description of an invention is
sufficiently enabling because "small changes to the structure of the
invention may lead to vastly different behaviors."045 They provide the
example of "a very minor alteration to a functional chemical compound that
may render it inert for a particular purpose."3 4 6 For this reason, they note
that "patent specifications within unpredictable arts must prove more than a
few illustrations in order to support a broadly drafted generic claim."347
Patent applicants must therefore render references to social categories of
race as unproblematic-not a difficult task given the apparently low level of
342. Id.
343. SCHECTER & THOMAS, supra note 3, at 393-94.
344. See, e.g., THE CONCEPT OF "RACE" IN NATURAL AND SOCIAL SCIENCE passim (Nathaniel E.
Gates ed., 1997); AAA, Response, supra note 43; AAA, Statement, supra note 43.
345. SCHECTER & THOMAS, supra note 3, at 397.
346. Id.
347. Id.
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scrutiny given to racial claims in biotechnology patents. Yet given the
contingent, socially constructed, and temporally variable nature of race, one
might argue that race itself should be considered a sort of "unpredictable
art." If so constructed, racial patents would require far more careful and
elaborated definitions of race than are currently employed. Existing
biotechnology patents, however, employ race as an unproblematic, fixed,
and predictable construct. As such, these patents also "enable" a simplistic
conception of social race in order to produce a reified conception of race as
genetic.
B. PATENTING RACE: THE POLITICAL GEOGRAPHY OFRACIALI)ED PA TENTS
1. Refining Social Race into Genetic Race
348
A "product of nature" cannot be patented. To be rendered
patentable, it must be "purified and isolated" through human interventions
to produce a substance that does not otherwise exist.349 Historically, this
involved complex chemicals such as adrenaline. In the genomic era,
however, it has come to encompass engineered cDNA that is synthesized in
vitro by using an enzyme (reverse transcriptase) that produces a molecule
containing only those nucleotide sequences from the original DNA that
code for proteins (exons). While clearly scientific and technical in origin,
isolation and purification are distinctively legal concepts when it comes to
granting a patent.35 The PTO has asserted that "the inventor's discovery of a
gene can be the basis for a patent of the genetic composition isolated from its
natural state and processed through purifying steps that separate the gene from
other molecules naturally associated with it."
3 52
Sheila Jasanoff observes that "[b]iotechnology ... renders continually
problematic the boundary between the natural and the unnatural. 3 53 The
authoritative discourses of science and law, however, are rendered
precarious by such uncertainty. Those seeking the legal recognition of
patentability for biotechnological achievements work hard to resolidify and
naturalize the boundary between natural and unnatural. Thus, the PTO
recognizes arguments that scientific intervention creates a patentable object
by severing it from its "natural associations."355 The PTO constructs cDNA as
348. Id. at 297.
349. Kahn, What's the Use, supra note 15, at 426, 438.
350. See, e.g., Parke-Davis & Co. v. Mulford Co., 189 F. 95, 95 (S.D.N.Y. 1911).
351. Kahn, What's the Use?, supra note 15, at 426.
352. Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001) (emphasis
added).
353. Sheila Jasanoff, The Life Sciences and the Rule of Law, 319 J. MOLECULAR BIOLOGY 891,
895 (2002).
354. Kahn, What's the Use?, supra note 15, at 419.
355. Id. at 426-27.
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isolated, not only in the sense of separating exons from introns, but more
powerfully, in the sense of separating the genetic material itself from nature.
This is not a scientific process but a legal one. The scientist may create
11i6
cDNA, but the PTO draws the line between nature and artifice. 6 Similarly,
purification involves stripping the genetic material of its identity as a part of
nature-ridding it of its "natural associations."
In contrast, race enters the world of biotechnology as a social construct,
often in the form of OMB Directive 15 classifications.157 It serves as a
surrogate for presumed underlying genetic variations in particular
populations. 358 In the patent and drug approval process, race is implicitly
recoded as a genetic categorys 59 The patent process takes race as a social
category and recodes it as natural by according it legal force as a component
160
of a biotechnological invention. In cases such as BiDil, the patent and
drug approval process produces a transformed understanding of race as
genetic when the end product is marketed to the public. BiDil obtained its
commodity value from the rebiologization of race in the regulatory process.
In the context of gene patents, genetic race literally became a commodity as
the race-specific patent allowed NitroMed to raise venture capital and
develop a marketing strategy that ultimately led to the commercial launch of
BiDil in June 2005, after FDA approval. In the course of its strategic
commodification of race, NitroMed presented a reified conception of
African American-ness as genetic to doctors, regulators, and the public at
361large.
Of course, race has a long history of being commodified in this
country.3 62 Beyond the most egregious form of chattel slavery, race was also
implicitly constructed as a form of property to buttress the Jim Crow laws of
the late nineteenth century until Brown v. Board of Education struck down the
doctrine of separate but equal in 1954.363 The Supreme Court's decision in
Plessy v. Ferguson laid the constitutional foundation for decades of Jim Crow
laws by upholding an 1890 Louisiana statute "providing for separate railway
carriages for the white and colored races. "0 64 Homer Plessy, a resident of
New Orleans, was seven-eighths White and one-eighth Black. On June 7,
356. Id.
357. See supra text accompanying notes 83-98.
358. See supra text accompanying notes 213-91.
359. Id.
360. Id.
361. Kahn, False Promises, supra note 166, at 8-9 (noting that NitroMed asserted in a press
release that "'African Americans between the ages of 45 and 64 are 2.5 times more likely to die
from heart failure than Caucasians in the same age group'").
362. Harris, supra note 18, at 1720-21.
363. Id. at 1745-57 (citing Brown v. Bd. of Educ., 347 U.S. 483 (1954)).
364. Plessy v. Ferguson, 163 U.S. 537, 540 (1895).
365. Id. at 538.
[20071
RA CE-ING PA TENTS/PA TENTING RACE
1892, Plessy bought a first-class ticket on the East Louisiana Railway for
passage from New Orleans to Covington, Louisiana, and took a seat reserved
for White passengers.
3 66 He was arrested for violating the separate-car law.
367
As Charles Lofgren notes, the arrest "was surely arranged," because, as his
counsel later asserted, "'the mixture of colored blood [was] not discernible"'
in him-i.e., he "appeared" to be White.
3 6 s
Cheryl Harris persuasively argues that a central component of Plessy was
a dispute over the plaintiff's claim to a property interest in his reputation as
a White person.369 A brief filed by Plessy's attorneys asserted that
"[r]eputation is a species of property... and is valuable in proportion as it
entails rights and privileges, whether social or political."3 70 Justice Brown
rejected this argument, largely on procedural grounds, asserting that any
such claims could be asserted as a matter of civil tort independent of a
challenge to the constitutionality of the law and hence, were not the
concern of the Supreme Court in this case: Specifically, Brown asserted:
[I]f [Plessy] be a white man, and assigned to a colored coach, he
may have his action for damages against the company for being
deprived of his so-called "property." Upon the other hand, if he be
a colored man, and be so assigned, he has been deprived of no
property, since he is not lawfully entitled to the reputation of being
372a white man.
This rhetorical gesture, argues Harris, implicitly recognized and protected a
property value in "whiteness. "
3
Building on Harris's work, J. Allen Douglas notes that "while the courts,
following Plessy [and its reference to civil remedies for racial
misrepresentation], treated whiteness as an object possessed, they
determined the meaning of that object through its representation in the
community, the very same means by which courts recognized and
constructed reputation." 74 The very need to appeal to representation in the
community implied a sort of instability and mutability to race that was very
threatening to a social order built on White supremacy. In this context,
Douglas argues, Plessy and its progeny can be understood as attempts "to
locate racial identity in the body in the form of an object or property-an
366. Id.
367. Id. at 538-39.
368. CHARLES LOFGREN, THE PLESSYCASE: A LEGAL-HISTORICAL INTERPRETATION 41 (1987).
369. Harris, supra note 18, at 1746-50.
370. LOFGREN, supra note 368, at 55.
371. Plessy, 163 U.S. at 549.
372. Id.
373. Harris, supra note 18, at 1750.
374. J. Allen Douglas, The "Most Valuable Sort of Property" ' Constructing White Identity in
American Law, 1880-1940, 40 SAN DIEGO L. REV. 881,896 (2003).
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immutable, natural 'thing' possessed-to ensure a means for 'quieting title'
in whiteness.
"
0
75
Justice Brown's opinion effectively denied Plessy's claim to property in a
reputation as White. If Plessy "be a colored man,"376 he could not claim
injury to reputation because it did not accord with the Court's implicit
understanding of the "reality" of race as something fixed and determinable.
Nonetheless, the same if-then structure of Brown's qualification of Plessy's
claim also raised the specter of racial indeterminacy-that Plessy's racial
identity might not be immediately obvious. Thus, in the very act of trying to
"quiet title" to Whiteness, the majority opinion in Plessy underlined the
problematic nature of the state's project of forced racial identification.
In a similar dynamic, the background and description sections of
racialized patents often acknowledge the indeterminacy of race as a social
construct, used as a surrogate for uncovering underlying genetic differences.
But in the legally operative claims sections, such indeterminacy is effaced
and race is naturalized as a fixed genetic category as the patent applicant
tries to "quiet tile" to race as he or she draws a clear and unequivocal ring
of race to defend the metes and bounds of a patent. Such legally sanctioned
reified racial categories draw additional strength from the underlying
premise that patents have the power to mark boundaries between the worlds
of nature and culture. As a patent legitimizes the use of race as a fixed
genetic category, it constructs race as natural and objective. Patentability
here is premised on a falsely constructed "discovery" of a mischaracterized
connection between two purportedly "natural" phenomena-race and
genetics.
As corporations and markets come to attach commercial value to race
as a genetic commodity, there will be increased incentives to produce more
examples of race as genetic in a commercial context. It is almost as if social
categories of race are being used as seed money to produce genetic race as a
commodity. Alternatively, social race may here be viewed as analogous to a
sort of raw material that the patent process refines (i.e., purifies and strips of
its "social associations") into a "novel" and "useful" manufactured product
composed of genetic race. In patenting race, biotechnological inventions
actually produce race as genetic.
2. The Segregated Genome
Continuing with the Jim Crow analogy, it is useful to compare genomes
racialized through biotechnology patents with the legally managed
production of racially identified neighborhoods in residential communities.
John Calmore refers to the "racialization of space" as "the process by which
residential location and community are carried and placed on racial
375. Id. at 899.
376. Plessy, 163 U.S. at 549.
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identity." 7 Through a series of legal and regulatory interventions, ranging
from racially restrictive covenants to zoning laws and sanctioned red-lining,
specific social and residential spaces have become racially marked and
segregated over time.: 7s Calmore hypothesizes that for Whites, "[t]he
compoundness of race and space ... [is] taken for granted; white space is
not problematic and black space is somewhere else. For Whites, the broad
notion of housing simply does not present the problems that it has for
blacks." ' In a similar manner, those who submit racialized patents to the
government for approval are using the legal system to inscribe portions of
the genome (usually identified as areas of differing allele frequency) with
distinct racial identities. Thus, for example, while the description section of
a patent may assert that a particular allele frequency is lower or higher in
Asians, the claims section will definitively mark that segment of the genome
as Asian. Such inscription, in effect, creates a segregated genome with Black,
White, Asian, Hispanic, etc. neighborhoods.
Patents exploit such racialized neighborhoods of the genome to build
defensive claims and provide a basis for literally capitalizing on race. Unlike
residential segregation, biotechnology patents have the added convenience
of being able to make use of racially marked genes without having to deal
with the troubling presence of actual human bodies. Living individuals who
share the racial identities being exploited in biotechnology patents would
likely have no more success in challenging such patents than individuals who
have objected more broadly to patents covering any human genetic material
as an affront to human dignity or as an impermissible commodification of
the common heritage of human kind.3' ° This is for the simple reason that,
like other human gene patents, the actual personal DNA of such concerned
individuals would not be at issue, and the patent system is unlikely to
acknowledge a more amorphous claim to appropriation of racial identity in
the context of biotechnology patents.
3
In the context of biotechnology patents, race becomes a statistical
concept based on molecular correlations and frequencies-not on the
embodied experiences of real people walking in real time through physical
space. Traditional legal schemes of embodied segregation in the United
States were based on the concept of "hypodescent" where "one drop of black
blood" was sufficient to consign a living person to the marked racial category
377. John 0. Calmore, Racialized Space and the Culture of Segregation: "Hewing a Stone of Hope
from a Mountain of Despair, " 143 U. PA. L. REv. 1233, 1235 (1995).
378. See generally Keith Aoki, Space Invaders: Critical Geography, the "Third World" in
International Law and Critical Race Theory, 45 VILL. L. REv. 913 (2000); Calmore, supra note 377;
Ford, supra note 18.
379. Calmore, supra note 377, at 1234.
380. Kahn, What's the Use?, supra note 15, at 424, 429.
381. Kahn, Biotechnology and the Legal Constitution of the Self supra note 15, at 927-30.
92 IOWA LA WREVIEW
312
of Black. In the new statistically informed legal schemes of biotechnology
patents, it is "one drop of correlation" that provides the basis for making
claims that segregate the genome into racially identified neighborhoods-
the slightest correlation of variable allele frequencies with particular racial
groups racializes the alleles, which in turn geneticizes race. 3 Some of these
racial neighborhoods may be marked as genomic ghettos, areas associated
with blight, disease, or weakness. But, as with contemporary dynamics of
384urban gentrification, a blighted neighborhood may also present a
distinctive opportunity for development-as NitroMed discovered with
BiDil.
Genomic segregation thus keeps races separate in order to develop and
market products. It manages relations among haplotype blocks and SNP
frequencies rather than housing patterns or school enrollments. The
racialized patent divorces race from the body, reducing it to a function of
correlation and allelic frequencies. Thus molecularized, race is more readily
susceptible to scientific and commercial manipulations to appropriate its
value in a manner that both naturalizes it as genetic and inhibits
interference from living individuals who represent embodied claims to a
particular racial identity.
Richard Thompson Ford notes that "[s]pace, as we experience it, is in
many ways the product, and not the fixed context, of social interactions,
ideological conceptions, and of course, legal doctrine and public policy."
38 5
Ford argues that political space-space that is produced, identified, and
maintained through legal and political processes-is often tacitly
understood as either opaque (natural and pre-political) or as transparent in
386the sense of being obvious and given . In a manner similar to Duster's
discussion of the complex feedback loops that produce dynamic relations
between race and biology, 87 Ford criticizes both extremes of understanding
as misconceiving the complex dynamics that go into the production of
political space.388 Ford discusses political space in the context of residential
segregation, wherein:
The conception of space as transparent corresponds to a view of
local governments as mere delegates of state power, without
382. NOBLES, supra note 83, at 135-36. See generally MICHAEL OMI & HOWARD WINANT,
RACIAL FORMATION IN THE UNITED STATES: FROM THE 1960S TO THE 1990S (2d ed. 1994)
(exploring concepts, change, focus, and permeation of race in society).
383. See Duster, supra note 31, at 1050-51.
384. Keith Aoki, Race, Space, and Place: The Relation Between Architectural Modernism, Post-
Modernism, Urban Planning, and Gentrification, 20 FORDHAM URB. L.J. 699,699-830 (1993).
385. Ford, supra note 18, at 1859.
386. Id. at 1859-61.
387. See supra text accompanying note 144 (discussing Duster's argument that race
interactions should be investigated in relation to biological functioning and medical practice).
388. Ford, supra note 18, at 1858-60.
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autonomy or independent political significance. The conception of
space as opaque corresponds to a view that sees local governments
as autonomous sovereigns, or that analogizes local governments to
private citizens, regarding them as unproblematically unified and
self-validating entities, with rights against both outsiders and
centralized authority.
389
In Ford's terms, we can see that the PTO and the FDA occupy the position
of mere transparent reviewers of the information applicants provide to
them. Their acts are largely viewed as reactive and constructed as
autonomous of independent political significance. The applicants, in turn,
become opaque, or unproblematically unified and self-validating, in their
racialization of the space of biotechnology patents. Their use of the legal
regime of intellectual property to, in effect, zone the genome into racially
identified neighborhoods goes unchallenged and, indeed, unnoticed.
Ford, however, is concerned that the perception of space as neutral
rather than as political maintains and perpetuates segregation. He argues in
particular that "political space does the work of maintaining racially
identified spaces, while reified political boundaries obscure the role of
political space and represent it either as the delegation of state power and
therefore inconsequential, or as natural and therefore inevitable."'3 90 In the
context of biotechnology patents, race itself is also viewed as either opaque
or transparent. Opaque race is genetic race. It is reified as complex, pre-
political, and natural. Transparent race is social race. It is implicitly devalued
as obvious and hence constructed as irrelevant or at most instrumental to
the assertion of a racialized patent claim. Such a construction of race creates
and perpetuates the genomic segregation necessary for pseudo-
pharmacogenomic race-specific product development that is emerging in
the gap between today's biomedical realities and tomorrow's promise of
truly individualized medicine.
The construction of opaque and transparent conceptions of race in
racial patents may be understood as an emerging process of "racial
formation," which Omi and Winant define as "the sociohistorical process by
which racial categories are created, inhabited, transformed and
destroyed."09 This process involves "racial projects"9 in which "human
bodies and social structures are represented and organized. 9 3 Racial
projects, in turn, play a central role in the evolution of hegemony, which
389. Id. at 1861.
390. Id. at 1877.
391. OMI & WINANT, supra note 382, at 55.
392. Omi and Winant define "racial projects" as "simultaneously an interpretation,
representation, or explanation of racial dynamics, and an effort to reorganize and redistribute
resources along particular racial lines." Id. at 56.
393. Id.
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ultimately is administered or legitimized through a variety of affirmative
sanctions of a "racial state."394 Racialized biotechnology patents function as a
sort of racial project that organizes racially marked molecules rather than
bodies per se. Once instantiated, race in patents provides a further basis for
allocating power and control, or hegemony, over the genomic invocation of
race. As approved by federal agencies such as the PTO and the FDA, race in
biotechnology patents ultimately becomes a project of a racial state that
lends official sanction to the reification of race as genetic.
Drawing on the work of critical geographers such as Edward Soja and
David Harvey, Keith Aoki notes that "[s]paces are produced and maintained
by a dynamic set of factors. . . . [I]nvestment capital may be distributed
unevenly to certain neighborhoods .... Particular nations, regions, cities,
and areas within cities prosper and thrive, while others decline and
whither.0 9 5 The racialized spaces of NitroMed's BiDil and Myriad's BRCA2
patent provided a basis for directing the flow of capital to the patent
396holders. In these cases, racial marking made the neighborhood of the
patented biotechnology more valuable. Significantly, however, the added
value provided by race is appropriated by the patent holder-the landlord,
so to speak-rather than by the community whose race has been
commandeered into the service of producing the relevant product. Indeed,
to the extent that a patent is conceived of as a right to exclude others from
use of a particular invention, a racialized patent gives the patent holder the
right to exclude members of the identified races from access to or control
over the terms through which the patent process appropriates and
commodifies their racial identity. Patents place the refinement of race from
a social into a genetic category beyond the reach of the implicated racial
communities.
As Audrey McFarlane notes in the context of her analysis of the
Empowerment Zone Program, which aimed to help marginalized poor and
minority communities, "the reality is that most of the development projects
are controlled by professional community development corporations that
allow for varying degrees of community control of input." '97 The
Empowerment Zone Program was justified by promising to provide jobs to
needy communities, but McFarlane notes that the "true beneficiaries" were
"established business and governmental elites."098 Similarly, NitroMed, in
bringing BiDil to market, enlisted the support of such groups as the
Association of Black Cardiologists ("ABC") and the Congressional Black
394. Id. at 82.
395. Aoki, supra note 384, at 918-19.
396. Sankar & Kahn, supra note 65, at W5-460-62; Kahn, Racial Categories, supra note 8, at
28-32.
397. Audrey G. McFarlane, Race, Space, and Place: The Geography of Economic Development, 36
SAN DIEGO L. REv. 295, 306-07 (1999).
398. Id. at 347.
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Caucus. 39 NitroMed and the researchers it supported have justified its race-
400
specific approach by promising to save lives -even though there was no
401scientific evidence that race had anything to do with the drug's efficacy.
On the eve of the FDA meeting to review BiDil, many Black-identified
groups, including the ABC and the International Society for Hypertension
in Blacks, unsuccessfully argued for BiDil's approval for use in the general
population, but argued against granting it a race-specific indication out of
402
concern for the dangers of reifying race. In the end, NitroMed got its403
way. In getting its billion-dollar drug to the market, NitroMed
appropriated the value of racially identified advocacy groups, just as it
appropriated the value of racially identified genes.
VIII. CONCLUSION
The implications of the striking rise of race in biotechnology patents
have yet to fully develop. Federal mandates and intellectual property law
have played a central role in shaping the production, classification, and
circulation both of genetic data and racial categories in biotechnology
research and product development. In the case of BiDil and the Myriad
Genomics BRCA2 test, we see how racialized patents are coming to play a
central role in biotechnology research, development, and marketing. Both
involve technologies that were already in use. Adding race to the patents did
not change the technology so much as it provided an added incentive to
market and extend monopoly control for the product. Their example
provides a model to transform what may have initially been a defensive use
of race in patent protection to affirmative projections of race as a central
component of product development and marketing. In the case of BiDil,
race also unmistakably added publicity value to the product. A good deal of
publicity was produced by social understandings that reified race as genetic.
For example, in addition to casual references to a race-specific genetic basis
for BiDil's efficacy in the popular media, articles published in scientific and
professional journals such as Genome Biology,
40 4 the British Medical Journa
4 °5
and Health Affairs40 6 have also incorrectly asserted that a genetic variation
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more prevalent in self-identified African Americans underlies BiDil's
efficacy.
The striking rise of racialized biotechnology patents indicates that cases
like BiDil are paving the way for a proliferation of applications producing
new, highly problematic understandings of race as genetic. BiDil obtained its
commodity value from the rebiologization of race in the regulatory process.
Additional racial patents, for products not yet as prominent as BiDil, have
secured regulatory imprimatur for using race as a genetic category.4 °7 Like
more traditional extractive industries, biotechnology corporations are
mining the raw material of race as a social category and using the patent
process to refine it into a natural construct, lending legal utility and novelty
to their inventions. The patents are in place and proliferating, ready to be
invoked to protect a product or extend a market. In the context of gene
patents, genetic race is becoming a commodity as race-specific patents allow
biotechnology corporations to raise venture capital and develop marketing
strategies that present a reified conception of race as genetic to doctors,
regulators, and the public at large. In the process, racialized biotechnology
patents are also marking neighborhoods of the genome with racial identities
as they both produce and appropriate a new genetic commodity value in
race.
407. See supra notes 213-89 and accompanying text.
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